var title_f1_26_1440="Nail lateral longitudinal excision";
var content_f1_26_1440=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral longitudinal excision of the nail",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_26_1440=[""].join("\n");
var outline_f1_26_1440=null;
var title_f1_26_1441="Pomeroy tubal ligation C";
var content_f1_26_1441=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pomeroy tubal ligation C",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Segment of tube being excised.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_26_1441=[""].join("\n");
var outline_f1_26_1441=null;
var title_f1_26_1442="Exercise-induced asthma";
var content_f1_26_1442=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Exercise-induced asthma (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/26/1442/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1442/contributors\" id=\"au2558\">",
"       Paul M O'Byrne, MB, FRSC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/26/1442/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1442/contributors\" id=\"se5257\">",
"       Peter J Barnes, DM, DSc, FRCP, FRS",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?1/26/1442/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1442/contributors\" id=\"de1810\">",
"       Helen Hollingsworth, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?1/26/1442?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      EXERCISE-INDUCED ASTHMA OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Exercise-induced asthma occurs when the airways narrow as a result of exercise. The preferred term for this condition is exercise-induced bronchoconstriction (EIB); exercise does not cause asthma, but is frequently an asthma trigger.",
"    </p>",
"    <p>",
"     A person may have asthma symptoms that become worse with exercise (more common) or may have only exercise-induced bronchoconstriction, without symptoms at other times. If a person's asthma is triggered only during vigorous exercise (exercise-induced bronchoconstriction), they are considered to have mild intermittent asthma. Separate topic reviews discuss asthma in children and adults. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"      \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=see_link\">",
"      \"Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      EXERCISE-INDUCED ASTHMA SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Typical symptoms are shortness of breath, chest tightness, and cough. Exercise-triggered symptoms typically develop 10 to 15 minutes after a brief episode of exercise or about 15 minutes into prolonged exercise. Symptoms typically resolve with rest over 30 to 60 minutes. Exercise-induced symptoms occur more commonly and are more intense when the inhaled air is cold, probably due to changes in the airways that are triggered by the large amounts of relatively cool, dry air inhaled during vigorous activity. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"      \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     EIB is different than simple shortness of breath related to exercise, which generally resolves within five minutes of stopping exercise.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      EXERCISE-INDUCED ASTHMA PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     Preventing exercise-induced bronchoconstriction usually includes use of an inhaled medication. Several options are available.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Rapid-acting bronchodilator",
"     </span>",
"     &nbsp;&mdash;&nbsp;Inhalation of a rapid-acting bronchodilator (eg, two puffs of albuterol or 1 inhaled formoterol capsule) may be taken approximately 10 minutes before exercise. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=see_link\">",
"      \"Patient information: Asthma inhaler techniques in children (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"      \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Cromolyn sodium",
"     </span>",
"     &nbsp;&mdash;&nbsp;Inhaled cromolyn sodium (Intal&reg;) may be used before exercise, sometimes in combination with a rapid-acting inhaled bronchodilator. When taken via metered dose inhaler, the dose of cromolyn is two puffs, 15 to 20 minutes before exercising. However, in the United States, cromolyn is only available as a nebulizer solution.",
"    </p>",
"    <p>",
"     Cromolyn sodium works by decreasing the activity of allergy cells. This medicine has no side effects. It is sometimes less effective than albuterol, although some patients prefer it due to the lack of side effects. It is important to understand that cromolyn sodium is used for",
"     <strong>",
"      prevention",
"     </strong>",
"     of symptoms",
"     <strong>",
"      ONLY",
"     </strong>",
"     . Cromolyn does",
"     <strong>",
"      NOT",
"     </strong>",
"     relieve symptoms once they have developed. If asthma symptoms develop despite pretreatment with cromolyn, a rapid-acting bronchodilator (eg, albuterol) should be used.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      For children or active adults",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some adults and most children exercise intermittently throughout the day, making it hard to use a preventive treatment before each episode of activity. In this case, a long-acting inhaled bronchodilator (eg, salmeterol or formoterol) or a leukotriene modifier (eg, montelukast or zafirlukast) may be recommended to provide day-long protection (see",
"     <a class=\"local\" href=\"#H8\">",
"      'Leukotriene modifiers'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Long-acting bronchodilators",
"     </span>",
"     &nbsp;&mdash;&nbsp;Long-acting bronchodilators (LABAs) such as salmeterol and formoterol work for a longer period than rapid-acting bronchodilators. LABAs are not recommended as a single treatment for asthma, but should instead be used with an inhaled glucocorticoid or a leukotriene modifier. Inhalers that contain both a LABA and a glucocorticoid are recommended (eg, Advair&reg;, Seretide&reg; in Europe, Symbicort). Salmeterol should be taken at least 30 minutes and formoterol at least 5 minutes before exercise. Do not repeat these more frequently than every 12 hours.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Leukotriene modifiers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Leukotriene modifiers work by decreasing airway narrowing, inflammation, and mucus production. Examples of leukotriene modifiers include montelukast (Singulair&reg;) and zafirlukast (Accolate&reg;). These are taken in pill form by mouth once daily (montelukast) or twice daily (zafirlukast), and have few side effects. Taken regularly, either of these medications is useful in preventing exercise-induced bronchospasm.",
"    </p>",
"    <p>",
"     Leukotriene modifiers may be used as an alternative to rapid-acting bronchodilators to prevent exercise-induced bronchoconstriction for patients who prefer or need all-day protection or have difficulty using inhalers.",
"    </p>",
"    <p>",
"     Montelukast is approved for use as needed before exercise for patients who do not require daily medication. Montelukast should be taken at least two hours before the start of exercise; protection lasts for approximately 12 hours. The medication should only be taken once in 24 hours.",
"    </p>",
"    <p>",
"     Leukotriene modifiers are used for",
"     <strong>",
"      prevention",
"     </strong>",
"     of symptoms",
"     <strong>",
"      ,",
"     </strong>",
"     <strong>",
"      NOT",
"     </strong>",
"     for relief of symptoms once they have developed. If asthma symptoms develop despite pretreatment with a leukotriene modifier, a rapid-acting bronchodilator (eg, albuterol) should be used.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      ASTHMA ATTACK TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The term \"asthma attack\" is somewhat confusing because it does not distinguish between a mild increase in symptoms and a life-threatening episode. Asthma symptoms may develop during exercise despite pretreatment and may sometimes be more severe than expected. Exercise induced asthma symptoms may be aggravated by changes in air quality, common colds, exposure to allergens, or changes in the weather. These triggers can cause mild, moderate, or severe symptoms to develop. Any of these changes could be considered an asthma \"attack.&rdquo;",
"    </p>",
"    <p>",
"     Some people have periodic, mild attacks that never require emergency care, while others have severe and sudden attacks that require a call for emergency medical services.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Emergency care plan",
"     </span>",
"     &nbsp;&mdash;&nbsp;A patient or parent should work with a healthcare provider to formulate an emergency care plan that explains specifically what to do if symptoms worsen.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Mild attacks: Take two puffs of a rescue medication (eg, inhaled rapid-acting bronchodilator, such as albuterol). This may be repeated twenty minutes later, and then periodically (every two to four hours) until symptoms are improved. People who take controller medications, such as inhaled glucocorticoids, should also increase the dose of these and contact their provider for further instruction.",
"      </li>",
"      <li>",
"       Severe attack: Take two to six puffs of a rescue medication, depending upon how much the individual can tolerate at once without becoming too jittery. For patients with home nebulizer machines, two treatments can be given, 20 minutes apart.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If symptoms worsen or do not improve after initial use of a rescue medication, someone should immediately call for emergency medical assistance. Severe asthma attacks can be fatal if not treated promptly.",
"    </p>",
"    <p>",
"     In most areas of the United States, emergency medical assistance is available by calling 911. Patients should",
"     <strong>",
"      not",
"     </strong>",
"     attempt to drive to the hospital and should not ask someone else to drive. Calling 911 is safer than driving for two reasons:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       From the moment EMS personnel arrive, they can begin evaluating and treating asthma. When driving in a car, treatment cannot begin until the person arrives in the emergency department.",
"      </li>",
"      <li>",
"       If a dangerous complication of asthma occurs on the way to the hospital, EMS personnel may be able to treat the problem immediately.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Following a severe asthma attack, the patient is usually given a three to ten day course of an oral glucocorticoid medication (eg, prednisone, prednisolone). This treatment helps to reduce the risk of a second asthma attack.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Wear medical identification",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many people with medical conditions wear a bracelet, necklace, or similar alert tag at all times. If an accident occurs and the person cannot explain their condition, this will help responders provide appropriate care.",
"    </p>",
"    <p>",
"     The alert tag should include a list of major medical conditions and allergies, as well as the name and phone number of an emergency contact. One device, Medic Alert&reg; (",
"     <a class=\"external\" href=\"file://www.medicalert.com/\">",
"      www.medicalert.com",
"     </a>",
"     ), provides a toll-free number that emergency medical workers can call to find out a person's medical history, list of medications, family emergency contact numbers, and healthcare provider names and numbers.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H121\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18220912\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/11/4275?source=see_link\">",
"      Patient information: Asthma in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/58/17315?source=see_link\">",
"      Patient information: Asthma in children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18220938\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/0/37892?source=see_link\">",
"      Patient information: Asthma symptoms and diagnosis in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/3/44083?source=see_link\">",
"      Patient information: Asthma inhaler techniques in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=see_link\">",
"      Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"      An overview of asthma management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=see_link\">",
"      Beta agonists in asthma: Acute administration and prophylactic use",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/471?source=see_link\">",
"      The use of chromones (cromoglycates) in the treatment of asthma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=see_link\">",
"      What do patients need to know about their asthma?",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/\">",
"      www.nhlbi.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Lung Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lungusa.org/\">",
"      www.lungusa.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Asthma and Allergy Foundation of America",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aafa.org\">",
"      www.aafa.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Allergy, Asthma, and Immunology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aaaai.org/patients.stm\">",
"      www.aaaai.org/patients.stm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American College of Allergy, Asthma, and Immunology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.acaai.org/allergist\">",
"      www.acaai.org/allergist",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?1/26/1442/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?1/26/1442?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1442/abstract/1\">",
"      Storms WW. Asthma associated with exercise. Immunol Allergy Clin North Am 2005; 25:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1442/abstract/2\">",
"      Lucas SR, Platts-Mills TA. Physical activity and exercise in asthma: relevance to etiology and treatment. J Allergy Clin Immunol 2005; 115:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1442/abstract/3\">",
"      Spooner CH, Saunders LD, Rowe BH. Nedocromil sodium for preventing exercise-induced bronchoconstriction. Cochrane Database Syst Rev 2002; :CD001183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1442/abstract/4\">",
"      Philip G, Villar&aacute;n C, Pearlman DS, et al. Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast. J Asthma 2007; 44:213.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f1_26_1442=[""].join("\n");
var outline_f1_26_1442=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           EXERCISE-INDUCED ASTHMA OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           EXERCISE-INDUCED ASTHMA SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           EXERCISE-INDUCED ASTHMA PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           ASTHMA ATTACK TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f1_26_1443="Pelvic xray intertrochanteric hip fracture";
var content_f1_26_1443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pelvic radiograph of intertrochanteric hip fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A left intertrochanteric fracture with severe valgus angulation and displacement of the lesser trochanter is seen on this anteroposterior radiograph of the pelvis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Koval KJ, MD and Zuckerman, JD, MD. Atlas of Orthopaedic Surgery: A Multimeidal Reference. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_26_1443=[""].join("\n");
var outline_f1_26_1443=null;
var title_f1_26_1444="Ciprofloxacin and hydrocortisone: Patient drug information";
var content_f1_26_1444=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ciprofloxacin and hydrocortisone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35826?source=see_link\">",
"     see \"Ciprofloxacin and hydrocortisone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/35/6706?source=see_link\">",
"     see \"Ciprofloxacin and hydrocortisone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F151824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cipro&reg; HC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F151825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cipro&reg; HC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ear infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701812",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ciprofloxacin, hydrocortisone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ear discomfort.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the ear only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Warm suspension in hands 1 to 2 minutes before putting drops in ear.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake suspension well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lie on your side with problem ear up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pull the outer ear outward and upward.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put drops in ear without touching dropper to ear. Stay on side for 2 minutes or put cotton plug in ear.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12202 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7CC26F0507-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_26_1444=[""].join("\n");
var outline_f1_26_1444=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151824\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151825\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024907\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024906\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024911\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024912\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024914\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024909\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024910\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024915\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024916\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/63/35826?source=related_link\">",
"      Ciprofloxacin and hydrocortisone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/35/6706?source=related_link\">",
"      Ciprofloxacin and hydrocortisone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_26_1445="Belatacept: Patient drug information";
var content_f1_26_1445=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Belatacept: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/41/43669?source=see_link\">",
"     see \"Belatacept: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13034487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nulojix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13110984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3484609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have a chance of getting post-transplant lymphoproliferative disorder (PTLD). PTLD happens when your white blood cells grow out of control and can lead to cancer and death.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700869",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will have more chance of getting infections. Avoid crowds and people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3484608",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may add to your chance of getting some types of cancer. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13110986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691580",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to protect the kidney transplant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13110985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3484602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to belatacept or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3484612",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have not been exposed to EBV (Epstein Barr) virus.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13110990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad infections have been reported with use of this drug. If you have any infection, are taking antibiotics now or in the recent past, or have many infections, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13110991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697868",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia and low white blood cell count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals and good mouth care may help. Older children may suck hard, sugar-free candy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13110993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Confusion; very nervous; anger with sweating, shivering, stiffness, or shaking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698642",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble speaking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3424302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Night sweats.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3424303",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13110988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used with other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13110995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16791 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.202-77C9F1D2D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_26_1445=[""].join("\n");
var outline_f1_26_1445=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13034487\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13110984\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13110986\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13110985\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13110990\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13110991\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13110993\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13110988\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13110995\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/41/43669?source=related_link\">",
"      Belatacept: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_26_1446="Montelukast: Pediatric drug information";
var content_f1_26_1446=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Montelukast: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"    see \"Montelukast: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/18/13605?source=see_link\">",
"    see \"Montelukast: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F197951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Singulair&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F197952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Montelukast;",
"     </li>",
"     <li>",
"      Dom-Montelukast;",
"     </li>",
"     <li>",
"      Dom-Montelukast FC;",
"     </li>",
"     <li>",
"      Jamp-Montelukast;",
"     </li>",
"     <li>",
"      Montelukast Sodium Tablets;",
"     </li>",
"     <li>",
"      Mylan-Montelukast;",
"     </li>",
"     <li>",
"      PMS-Montelukast;",
"     </li>",
"     <li>",
"      PMS-Montelukast FC;",
"     </li>",
"     <li>",
"      Sandoz-Montelukast;",
"     </li>",
"     <li>",
"      Sandoz-Montelukast Granules;",
"     </li>",
"     <li>",
"      Singulair&reg;;",
"     </li>",
"     <li>",
"      Teva-Montelukast",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Leukotriene Receptor Antagonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"      see \"Montelukast: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Allergic rhinitis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6 months to 5 years: 4 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-14 years: 5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;15 years: 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Asthma, chronic treatment and prophylaxis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     12 months to 5 years: 4 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-14 years: 5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;15 years: 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Asthma, exacerbation (acute), adjunct  therapy:",
"     </b>",
"     Limited data available: Oral: Children 2-5 years: 4 mg/dose; in a double-blind, placebo-controlled trial of 52 children with acute asthma exacerbation, a single dose of montelukast (4 mg) with concomitant short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist (salbutamol) showed lower respiratory rate and improved pulmonary indices compared to placebo (Harmanci, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bronchoconstriction, exercise-induced; prevention:",
"     </b>",
"     Oral: Administer dose at least 2 hours prior to exercise; additional doses should not be administered within 24 hours. Daily administration to prevent exercise-induced bronchospasm has not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adolescents 6-14 years: Chewable tablet: 5 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents &ge;15 years: Tablet: 10 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Asthma, allergic seasonal or perennial rhinitis:",
"     </b>",
"     Oral: 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bronchoconstriction, exercise-induced (prevention):",
"     </b>",
"     Oral: 10 mg at least 2 hours prior to exercise; additional doses should not be administered within 24 hours. Daily administration to prevent exercise-induced bronchoconstriction has not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     No adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild to moderate impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment: There are no dosage adjustments provided in the manufacturer labeling; has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F197926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules, oral: 4 mg/packet (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Singulair&reg;: 4 mg/packet (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Singulair&reg;: 10 mg [contains lactose 89.3 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral: 4 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Singulair&reg;: 4 mg [contains phenylalanine 0.67 mg/tablet; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Singulair&reg;: 5 mg [contains phenylalanine 0.84 mg/tablet; cherry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F197912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: When treating asthma, administer dose in the evening. Patients with allergic rhinitis may individualize administration time (morning or evening). Patients with both asthma and allergic rhinitis should take their dose in the evening.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Granules: May be administered directly into the mouth or mixed in cold or room temperature soft foods; based on stability studies, only applesauce, mashed carrots, rice, and ice cream should be used; granules are not intended to be dissolved in liquid (other than breast milk or infant formula) and must be administered within 15 minutes of opening the packet; liquids may be taken subsequent to administration.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1060452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from moisture and light; granules must be administered within 15 minutes of opening the packet.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis and chronic treatment of asthma (FDA approved in ages &ge;12 months and adults); relief of symptoms of seasonal allergic rhinitis (FDA approved in ages &ge;2 years and adults) and perennial allergic rhinitis (FDA approved in ages &ge;6 months and adults); prevention of exercise-induced bronchoconstriction (FDA approved in ages &ge;6 years and adults); has also been used as adjunct therapy for asthma exacerbation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F197994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Singulair&reg; may be confused with Oralair&trade;, SINEquan&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F197992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Children 6-23 months:",
"     </b>",
"     Respiratory: Cough, otitis media, pharyngitis, rhinitis, tonsillitis, upper respiratory infection, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Children 2 to &le;14 years:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Dermatitis, eczema, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, gastroenteritis, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Otic: Ear pain, otitis, otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Laryngitis, pharyngitis, pneumonia, rhinorrhea, sinusitis, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Influenza, varicella, viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Children &ge;15 years and Adults:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dental pain, dyspepsia, gastroenteritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Rare but important or life-threatening:",
"     </b>",
"     Anaphylaxis, angioedema, Churg-Strauss syndrome, depression, disorientation, eosinophilia (systemic), erythema multiforme, erythema nodosum, hallucinations, hepatic eosinophilic infiltration, hepatitis (mixed pattern, hepatocellular, and cholestatic), hypersensitivity, insomnia, pancreatitis, paresthesia, seizures, somnambulism, Stevens-Johnson syndrome, suicidal thinking/behavior (suicidality), suicide, thrombocytopenia, toxic epidermal necrolysis, vasculitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to montelukast or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution with concomitant administration of  potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin. Chewable tablets contain aspartame which is metabolized to phenylalanine and must be avoided (or used with caution) in patients with phenylketonuria. Some products may contain lactose; avoid use in patient with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Montelukast should not be used to treat exercise-induced bronchoconstriction if patient already on montelukast therapy for another indication (eg, chronic asthma).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1060447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Montelukast is not indicated for use in the reversal of bronchospasm in acute asthma attacks, including status asthmaticus; therapy with montelukast can be continued during acute exacerbations. A gradual reduction of inhaled corticosteroid therapy may be appropriate after beginning montelukast therapy; clinical monitoring and caution are recommended as montelukast is not a substitute for inhaled corticosteroid therapy. Montelukast will not interrupt bronchoconstrictor response to aspirin or other NSAIDs in susceptible individuals; patients with known aspirin sensitivity should continue to avoid these agents. Rare cases of systemic eosinophilia, sometimes presenting with clinical features of vasculitis (consistent with Churg-Strauss syndrome), have been reported; these reactions may also be associated with a reduction in oral corticosteroid dosage; a causal association with montelukast has not been established.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Postmarketing reports of behavioral changes including agitation, aggression, anxiousness, depression, disorientation, hallucinations, inattention, insomnia, irritability, memory impairment, somnambulism, suicidal thinking and behavior, and tremor have been observed in pediatric and adult patients. In a retrospective analysis performed by the manufacturer, the incidence of serious behavior-related events was rare (Philip, 2009); monitor and assess patients for behavioral changes; if occur, consider risks and benefits of continued therapy. Patients should be instructed to notify prescriber if behavioral changes occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F197980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F197921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F197923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F197934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Montelukast was not teratogenic in animal studies, however, there are no adequate and well-controlled studies in pregnant women. Based on limited data, structural defects have been reported in neonates exposed to montelukast",
"     <i>",
"      in utero",
"     </i>",
"     ; however, a specific pattern and relationship to montelukast has not been established. Healthcare providers should report any prenatal exposures to the montelukast pregnancy registry at (800) 986-8999.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1060455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pulmonary function tests (FEV-1), improvement in asthma symptoms, behavioral effects",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Montelukast is a selective leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT",
"     <sub>",
"      1",
"     </sub>",
"     receptor. This activity produces inhibition of the effects of this leukotriene on bronchial smooth muscle resulting in the attenuation of bronchoconstriction and decreased vascular permeability, mucosal edema, and mucus production.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 8-11 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive by cytochrome P450 3A4 and 2C9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg: 63% to 73%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg: 64%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg: 2-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Exclusively via bile; &lt;0.2% excreted in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/18/13605?source=see_link\">",
"      see \"Montelukast: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take regularly as prescribed, even during symptom-free periods. Do not use to treat acute episodes of asthma. Do not decrease the dose or stop taking any other asthma medications unless instructed by a physician. May cause mild headache, fatigue, or dizziness. Report skin rash or itching, abdominal pain or persistent GI upset, unusual cough or congestion, behavior and mood changes including depression and suicide ideation, feeling of numbness in arms or legs, flu-like illness, or worsening of asthmatic condition.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1060464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recent studies of montelukast use in acute asthma and RSV bronchiolitis have shown promising results. Pulmonary function tests improved significantly in adult patients receiving a single dose (10 mg) montelukast along with I.V. prednisolone at the onset of an acute asthma exacerbation (Cylly, 2003). Pediatric patients with RSV positive bronchiolitis receiving daily montelukast demonstrated fewer symptoms when compared with placebo treated controls (Bisgaard, 2003).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bisgaard H, \"A Randomized Trial of Montelukast in Respiratory Syncytial Virus Postbronchiolitis,\"",
"      <i>",
"       Am J Respir Crit Care Med",
"      </i>",
"      , 2003, 167(3):379-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/26/1446/abstract-text/12406832 /pubmed\" id=\"12406832 \" target=\"_blank\">",
"        12406832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cylly A, Kara A, Ozdemir T, et al, \"Effects of Oral Montelukast on Airway Function in Acute Asthma,\"",
"      <i>",
"       Respir Med",
"      </i>",
"      , 2003, 97(5):533-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/26/1446/abstract-text/12735671/pubmed\" id=\"12735671\" target=\"_blank\">",
"        12735671",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA)",
"      </i>",
"      , 2011. Available at file://www.ginasthma.org",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Guidelines for the Diagnosis and Management of Asthma. NAEPP Expert Panel Report 3,\" 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harmanci K, Bakirtas A, Turktas I, et al, \"Oral Montelukast Treatment of Preschool-Aged Children With Acute Asthma,\"",
"      <i>",
"       Ann Allergy Asthma Immunol",
"      </i>",
"      , 2006, 96(5):731-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/26/1446/abstract-text/16729788/pubmed\" id=\"16729788\" target=\"_blank\">",
"        16729788",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics &minus; 2002,\"",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2002, 110(5 Suppl):S141-219.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/26/1446/abstract-text/12542074/pubmed\" id=\"12542074\" target=\"_blank\">",
"        12542074",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Philip G, Hustad CM, Malice MP, et al, \"Analysis of Behavior-Related Adverse Experiences in Clinical Trials of Montelukast,\"",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2009, 124(4):699-706.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/26/1446/abstract-text/19815116/pubmed\" id=\"19815116\" target=\"_blank\">",
"        19815116",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Philip G, Hustad C, Noonan G, et al, \"Reports of Suicidality in Clinical Trials of Montelukast,\"",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2009a, 124(4):691-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/26/1446/abstract-text/19815114/pubmed\" id=\"19815114\" target=\"_blank\">",
"        19815114",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12620 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-18C9BB78CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_26_1446=[""].join("\n");
var outline_f1_26_1446=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197951\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197952\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060456\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060449\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197926\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197912\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060460\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060452\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060459\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197994\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197992\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060463\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060448\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060447\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197980\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197921\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197923\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F197934\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060455\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060446\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060462\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060454\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060464\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12620\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12620|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=related_link\">",
"      Montelukast: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/18/13605?source=related_link\">",
"      Montelukast: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_26_1447="Ovarian failure due to anticancer drugs and radiation";
var content_f1_26_1447=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ovarian failure due to anticancer drugs and radiation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/26/1447/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1447/contributors\">",
"     Corrine K Welt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1447/contributors\">",
"     Charles L Shapiro, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/26/1447/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1447/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1447/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/26/1447/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1447/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/26/1447/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several toxins can cause primary hypogonadism. Some are lifesaving therapies, such as anticancer drugs and radiation therapy. Others include cigarette smoke, chemicals, pesticides, viruses, and radioactivity. Anticancer drugs and radiation therapy are the most common of the known ovarian toxins, and will become an increasingly frequent cause of ovarian failure. It is estimated that up to 1 in 1000 persons under age 20 years will have been cured of cancer by these treatments by the year 2000, and many of them will have forgotten their treatment by the time they seek care for reproductive dysfunction. As an example, in a survey of 1928 adult survivors of childhood cancer, 14 percent denied having had cancer and 18 percent misclassified their treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/1\">",
"     1",
"    </a>",
"    ]. Ovarian failure due to anticancer drugs and radiation will be reviewed here. Other causes of premature ovarian failure and an overview of fertility in cancer survivors are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7817?source=see_link\">",
"     \"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=see_link\">",
"     \"Overview of fertility and pregnancy in cancer survivors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPEUTIC DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most anticancer drugs affect dividing cells and, therefore, would be expected to affect the granulosa and theca cells of the ovary more than the nondividing oocytes. However, the effect of these drugs on ovarian function varies widely, some having no effect and others causing permanent hypogonadism (",
"    <a class=\"graphic graphic_table graphicRef58142 \" href=\"UTD.htm?5/18/5421\">",
"     table 1",
"    </a>",
"    ). Typically, the ovaries of women who received chemotherapy have normal to mildly decreased numbers of primordial follicles and a greater decrease in the numbers of larger maturing follicles [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], indicating a greater effect on follicular development than on oocytes.",
"   </p>",
"   <p>",
"    Consistent with these histology findings are the clinical observations that many women, especially under 40 years of age, develop amenorrhea during chemotherapy, often with high serum gonadotropin concentrations, but menstrual function and, in some cases, fertility, may return several months to years after the cessation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alkylating drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , are the best documented and most potent at inducing ovarian failure. They alter base pairs, leading to DNA cross-links, and introduce single-strand DNA breaks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/7\">",
"     7",
"    </a>",
"    ]. As a result, they can theoretically affect both resting cells, such as oocytes, and dividing cells. The effects are age-, dose-, and drug-dependent. Younger women are affected less often than older women, presumably because they have more remaining oocytes. In one study, as an example, all women over age 40 years had amenorrhea after receiving more than 5.2 g of cyclophosphamide, whereas the dose required to cause amenorrhea in younger women was 9.5 g [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there is considerable variation in susceptibility, with some women having normal ovarian function but others of the same age having permanent primary hypogonadism after high doses of a single drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41496?source=see_link\">",
"     \"Acute side effects of adjuvant chemotherapy for early stage breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8202?source=see_link\">",
"     \"Patterns of relapse and long-term complications of therapy in breast cancer survivors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anti-M&uuml;llerian hormone ([AMH] also known as M&uuml;llerian inhibiting substance [MIS]) has been used as a biochemical marker of ovarian reserve (in addition to inhibin and FSH). Serum concentrations of AMH decline rapidly during chemotherapy, and may be useful for evaluating the ovarian toxicity of chemotherapy regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15720?source=see_link\">",
"     \"Ovarian development and failure (menopause) in normal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most women with cancer are treated with multiple drugs, so it is easier to evaluate the consequences of specific treatments rather than single drugs. In addition, standard treatment regimens changed over time. For example, MOPP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ), an early standard regimen used for Hodgkin's lymphoma, induced",
"    <strong>",
"     permanent",
"    </strong>",
"    primary hypogonadism in 12 to 46 percent of women treated, and the onset of amenorrhea was more rapid and its incidence was higher in those over age 24 years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/2,11,12\">",
"     2,11,12",
"    </a>",
"    ]. The wide range of primary hypogonadism is related, in part, to different definitions and duration of amenorrhea used in individual studies.",
"   </p>",
"   <p>",
"    Currently used regimens for Hodgkin's lymphoma have variable reproductive toxicities. The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    (ABVD) is the preferred therapy for most Hodgkin's lymphoma patients and it is associated with a low incidence of chemotherapy-induced ovarian failure. In contrast, with BEACOPP or escalated BEACOPP (bleomycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , doxorubicin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ), approximately 50 percent of women develop ovarian failure that is not prevented by use of oral contraceptives or GnRH analogues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In women with early stage breast cancer, two commonly used adjuvant chemotherapy regimens are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and 5-fluorouracil (CMF), and anthracycline-based regimens, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    plus cyclophosphamide (AC). In one study, the risk of ovarian failure appeared to be greater with CMF when compared with AC regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/13\">",
"     13",
"    </a>",
"    ]. The risk of ovarian failure with different adjuvant chemotherapy regimens for early breast cancer is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41496?source=see_link&amp;anchor=H15#H15\">",
"     \"Acute side effects of adjuvant chemotherapy for early stage breast cancer\", section on 'Chemotherapy-induced amenorrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The results in girls and young women treated with regimens specific for leukemia and solid tumors are different. In a study of 35 pre- and post-pubertal girls with leukemia who received various treatments, only three had primary hypogonadism a mean of 49 months after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/4\">",
"     4",
"    </a>",
"    ]; one had many residual follicles on ovarian biopsy and the other two resumed menses eight and 14 months later, suggesting they had a disorder of granulosa cell responsiveness rather than oocyte depletion. Girls with acute lymphoblastic leukemia treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (ara-C), and other drugs and cranial irradiation have a slightly early onset of puberty but high serum FSH and low inhibin concentrations, again suggestive of granulosa and thecal cell damage [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it would be ideal to modify chemotherapy regimens to minimize the negative effect on ovarian function, the primary focus of chemotherapy treatment in these situations is to maximize the probability of cure. The primary approaches to dealing with the ovarian complications of chemotherapy have included suppression of ovarian function and alternative fertility options, as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy is more damaging to ovarian tissue than is chemotherapy. Its effects also are dose- and age-dependent, but unlike chemotherapy radiation it is particularly toxic to oocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/15\">",
"     15",
"    </a>",
"    ]. Radiation toxicity varies with the cell cycle, being greatest during mitosis prenatally, the early stages of the first meiosis, and preovulatory maturation, so that small primordial oocytes are more sensitive to radiation than are oocytes in larger follicles [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/15\">",
"     15",
"    </a>",
"    ]. Especially in younger women, radiation can cause transient amenorrhea that resolves after 6 to 18 months, presumably after recruitment and development of a new cohort of primary follicles. Such a response also has been documented in women receiving radioactive iodine therapy for thyroid cancer, in whom approximately 30 percent had reversible primary hypogonadism [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although doses of more than 600 rads (6 Gy) consistently cause permanent primary hypogonadism in women over age 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/17\">",
"     17",
"    </a>",
"    ], the impact of lower doses varies, with reports of conceptions in women under 20 years of age who received up to 3000 rads (30 Gy) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Treatment of women with Hodgkin's lymphoma with pelvic irradiation in addition to chemotherapy increased the risk of ovarian failure from 0 percent to 68 percent in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study estimated the radiosensitivity of the oocyte to be &lt;2 Gy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/21\">",
"     21",
"    </a>",
"    ]. Based upon this estimate, the authors calculated the dose of radiotherapy that would result in immediate and permanent ovarian failure in 97.5 percent of patients as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      20.3 Gy at birth",
"     </li>",
"     <li>",
"      18.4 Gy at age 10 years",
"     </li>",
"     <li>",
"      16.5 Gy at age 20 years",
"     </li>",
"     <li>",
"      14.3 Gy at age 30 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these estimates have not been confirmed in other studies, they may be useful for counseling patients and families prior to initiating radiation therapy.",
"   </p>",
"   <p>",
"    It is important to note that most young women who are going to receive pelvic radiation therapy typically have an attempt to move the ovaries outside the field of radiation. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Oophoropexy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is no evidence for an increased rate of congenital anomalies in the offspring of women treated with chemotherapy, radiation therapy, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/23\">",
"     23",
"    </a>",
"    ]. There may, however, be an increase in the rate of early pregnancy loss [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/15\">",
"     15",
"    </a>",
"    ], and small for gestational age infants [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/24\">",
"     24",
"    </a>",
"    ], and an increased risk of malformations in fetuses exposed to radiation in utero. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=see_link\">",
"     \"Overview of fertility and pregnancy in cancer survivors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CHILDHOOD CANCER SURVIVORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian failure occurs in a significant percentage of childhood cancer survivors. In a report from the Childhood Cancer Survivor Study (CCSS) of 2819 survivors of childhood cancer over age 18 years and a control group of 1065 female siblings of participants in the CCSS, the cumulative incidence of premature ovarian failure in the survivor group was 8 percent compared with 0.8 percent in the siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Significant risk factors for nonsurgical premature menopause included older age at diagnosis, exposure to increasing doses of radiation to the ovaries (&ge;1000 cGy ovarian irradiation), increasing alkylating agent score (based on number of alkylating agents and cumulative dose), and a diagnosis of Hodgkin's lymphoma. The cumulative incidence of nonsurgical premature menopause was approximately 30 percent in survivors who had been treated with both alkylating agents and abdominopelvic radiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     FERTILITY PRESERVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for the preservation of fertility in women undergoing cytotoxic therapy are reviewed briefly here and discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prevention of ovarian failure",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Ovarian suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;In theory, ovarian toxicity from chemotherapy can be reduced by diminishing ovarian function during the period of treatment. This can be reversibly achieved by the administration of gonadotropin-releasing hormone (GnRH) agonists or oral contraceptives. In animals, GnRH agonists reduce the risk of chemotherapy-induced ovarian damage. The evidence in humans of a benefit from such an approach has been limited, but a meta-analysis of nine studies suggests that use of a GnRH agonist during chemotherapy may increase the rate of preserved ovarian function. The effect on fertility is uncertain. A randomized-controlled trial of GnRH agonists for ovarian suppression during breast cancer therapy demonstrates a decreased rate of primary ovarian insufficiency, although fertility outcome was not assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/26\">",
"     26",
"    </a>",
"    ]. Other trials may determine the fertility outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link&amp;anchor=H12#H12\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\", section on 'Gonadal suppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Oophoropexy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transposing the ovaries out of the radiation field is an option for preserving gonadal function in patients receiving pelvic radiation without chemotherapy. However, success rates with this procedure are inconsistent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link&amp;anchor=H11#H11\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\", section on 'Transposition (oophoropexy)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/47/6902?source=see_link\">",
"     \"Ovarian transposition before pelvic radiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cryopreservation techniques",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Embryos",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embryo cryopreservation is a well-established technique for storing surplus embryos of patients undergoing in vitro fertilization (IVF) procedures. With current freezing techniques, the implantation potential of frozen-thawed embryos approaches that of fresh embryos. However, cryopreservation of embryos may not personally or be technically feasible for every patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link&amp;anchor=H4#H4\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\", section on 'Embryo'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Oocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryopreservation of oocytes is an investigational procedure that is being studied as an option for women without partners who do not opt to use donor sperm for IVF. In contrast to cryopreservation of embryos and sperm, oocyte cryopreservation is technically more challenging since oocytes are more sensitive to cryoinjury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link&amp;anchor=H5#H5\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\", section on 'Oocytes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Ovarian tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another experimental prevention strategy is to obtain ovarian tissue for cryopreservation that can later be implanted. The potential advantages of this approach are that the tissue can be obtained without the need for ovarian stimulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link&amp;anchor=H3#H3\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\", section on 'Cryopreservation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oocyte and ovarian tissue cryopreservation are still considered investigational and it is recommended that patients undergo a research protocol when seeking these treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1447/abstract/27\">",
"     27",
"    </a>",
"    ]. Other fertility options for women with ovarian failure are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24807?source=see_link\">",
"     \"Oocyte donation for assisted reproduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14425?source=see_link\">",
"     \"Overview of treatment of female infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/5/19538?source=see_link\">",
"       \"Patient information: Early menopause (primary ovarian insufficiency) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/63/12276?source=see_link\">",
"       \"Patient information: Early menopause (primary ovarian insufficiency) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2023102\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women undergoing chemotherapy can develop amenorrhea, which may be temporary, or result in premature or early menopause.",
"     </li>",
"     <li>",
"      Chemotherapy effects on the ovary are age-, dose-, and drug-dependent, with alkylating agents the most potent.",
"     </li>",
"     <li>",
"      Radiation therapy, which is also age- and dose-dependent, is toxic to the oocytes, with permanent ovarian failure estimated at 97.5 percent of women with 18.4 Gy at age 10 years and 14.3 Gy at age 30 years.",
"     </li>",
"     <li>",
"      The rate of primary ovarian insufficiency in childhood cancer survivors is 8 percent.",
"     </li>",
"     <li>",
"      Oophoropexy should be used to remove the ovaries from the radiation field and embryo cryopreservation can be used before treatment if feasible. The effect of other potential fertility preservation treatments, such as GnRH agonists and oocyte or ovarian cryopreservation, is still considered investigational.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/1\">",
"      Byrne J, Lewis S, Halamek L, et al. Childhood cancer survivors' knowledge of their diagnosis and treatment. Ann Intern Med 1989; 110:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/2\">",
"      Warne GL, Fairley KF, Hobbs JB, Martin FI. Cyclophosphamide-induced ovarian failure. N Engl J Med 1973; 289:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/3\">",
"      Nicosia SV, Matus-Ridley M, Meadows AT. Gonadal effects of cancer therapy in girls. Cancer 1985; 55:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/4\">",
"      Siris ES, Leventhal BG, Vaitukaitis JL. Effects of childhood leukemia and chemotherapy on puberty and reproductive function in girls. N Engl J Med 1976; 294:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/5\">",
"      Bakri YN, Pedersen P, Nassar M. Normal pregnancy after curative multiagent chemotherapy for choriocarcinoma with brain metastases. Acta Obstet Gynecol Scand 1991; 70:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/6\">",
"      Hershlag A, Schuster MW. Return of fertility after autologous stem cell transplantation. Fertil Steril 2002; 77:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/7\">",
"      Epstein RJ. Drug-induced DNA damage and tumor chemosensitivity. J Clin Oncol 1990; 8:2062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/8\">",
"      Koyama H, Wada T, Nishizawa Y, et al. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977; 39:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/9\">",
"      Anderson RA, Cameron DA. Pretreatment serum anti-m&uuml;llerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 2011; 96:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/10\">",
"      Gracia CR, Sammel MD, Freeman E, et al. Impact of cancer therapies on ovarian reserve. Fertil Steril 2012; 97:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/11\">",
"      Stillman RJ, Schinfeld JS, Schiff I, et al. Ovarian failure in long-term survivors of childhood malignancy. Am J Obstet Gynecol 1981; 139:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/12\">",
"      Schilsky RL, Sherins RJ, Hubbard SM, et al. Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am J Med 1981; 71:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/13\">",
"      Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/14\">",
"      Quigley C, Cowell C, Jimenez M, et al. Normal or early development of puberty despite gonadal damage in children treated for acute lymphoblastic leukemia. N Engl J Med 1989; 321:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/15\">",
"      Baker TG. Radiosensitivity of mammalian oocytes with particular reference to the human female. Am J Obstet Gynecol 1971; 110:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/16\">",
"      Raymond JP, Izembart M, Marliac V, et al. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J Clin Endocrinol Metab 1989; 69:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/17\">",
"      Ash P. The influence of radiation on fertility in man. Br J Radiol 1980; 53:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/18\">",
"      GANS B, BAHARY C, LEVIE B. OVARIAN REGENERATION AND PREGNANCY FOLLOWING MASSIVE RADIOTHERAPY FOR DYSGERMINOMA. REPORT OF A CASE. Obstet Gynecol 1963; 22:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/19\">",
"      Horning SJ, Hoppe RT, Kaplan HS, Rosenberg SA. Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med 1981; 304:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/20\">",
"      Green DM, Yakar D, Brecher ML, et al. Ovarian function in adolescent women following successful treatment for non-Hodgkin's lymphoma. Am J Pediatr Hematol Oncol 1983; 5:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/21\">",
"      Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod 2003; 18:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/22\">",
"      Wallace WH, Thomson AB, Saran F, Kelsey TW. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 2005; 62:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/23\">",
"      Averette HE, Boike GM, Jarrell MA. Effects of cancer chemotherapy on gonadal function and reproductive capacity. CA Cancer J Clin 1990; 40:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/24\">",
"      Green DM, Sklar CA, Boice JD Jr, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27:2374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/25\">",
"      Sklar CA, Mertens AC, Mitby P, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006; 98:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/26\">",
"      Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011; 306:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1447/abstract/27\">",
"      ACOG Committee Opinion No. 405: ovarian tissue and oocyte cryopreservation. Obstet Gynecol 2008; 111:1255.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7432 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-FE4A772EBF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_26_1447=[""].join("\n");
var outline_f1_26_1447=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2023102\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHEMOTHERAPEUTIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CHILDHOOD CANCER SURVIVORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      FERTILITY PRESERVATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prevention of ovarian failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Ovarian suppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Oophoropexy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cryopreservation techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Embryos",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Oocytes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Ovarian tissue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2023102\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7432\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7432|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/18/5421\" title=\"table 1\">",
"      Ovarian failure anticancer Rx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41496?source=related_link\">",
"      Acute side effects of adjuvant chemotherapy for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=related_link\">",
"      Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24807?source=related_link\">",
"      Oocyte donation for assisted reproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15720?source=related_link\">",
"      Ovarian development and failure (menopause) in normal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/47/6902?source=related_link\">",
"      Ovarian transposition before pelvic radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7977?source=related_link\">",
"      Overview of fertility and pregnancy in cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14425?source=related_link\">",
"      Overview of treatment of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7817?source=related_link\">",
"      Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/63/12276?source=related_link\">",
"      Patient information: Early menopause (primary ovarian insufficiency) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/5/19538?source=related_link\">",
"      Patient information: Early menopause (primary ovarian insufficiency) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8202?source=related_link\">",
"      Patterns of relapse and long-term complications of therapy in breast cancer survivors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_26_1448="Prenatal diagnosis using cell-free fetal nucleic acids in maternal blood";
var content_f1_26_1448=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prenatal diagnosis using cell-free fetal nucleic acids in maternal blood",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/26/1448/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1448/contributors\">",
"     Adam Wolfberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1448/contributors\">",
"     Diana W Bianchi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/26/1448/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1448/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/26/1448/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1448/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/26/1448/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current methods of fetal genetic testing typically involve obtaining samples of amniotic fluid, placenta, fetal blood, or rarely, other fetal tissues or fluids. The invasive techniques required for obtaining fetal samples (eg, amniocentesis, chorionic villus biopsy, fetal venipuncture, fetoscopy-guided biopsy) place the fetus at risk of injury or death. Therefore, development of an accurate, safe, rapid, noninvasive test for prenatal diagnosis is an area of active investigation.",
"   </p>",
"   <p>",
"    Fetal genetic material can be found in the maternal circulation, raising the possibility of using maternal blood to diagnose fetal disease. Intact fetal cells can be identified in maternal blood, but are not a reliable source of fetal genetic material because these cells are extremely rare [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] and may persist for years after prior pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/3\">",
"     3",
"    </a>",
"    ]. By comparison, fetal \"cell-free\" nucleic acids (DNA and RNA) are more plentiful in the maternal circulation and unique to the current pregnancy. Thus, they have great potential for use in prenatal diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Where do fetal cell-free nucleic acids come from?",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DNA &mdash; Both the mother and the fetus produce cell free DNA. The primary source of fetal cell-free DNA in the maternal circulation is thought to be apoptosis of placental cells (syncytiotrophoblast), while maternal hematopoietic cells are the source of most maternal cell-free DNA [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]. There is some evidence that apoptosis of fetal erythroblasts also generates fetal cell-free DNA, which can cross the placenta and enter the maternal circulation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/4,7,8\">",
"       4,7,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      RNA &mdash; Both fetal and placental cells contribute cell-free mRNA to the maternal circulation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     When are fetal cell-free nucleic acids found in maternal blood?",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DNA &mdash; Fetal DNA can be isolated from maternal blood as early as the fifth postmenstrual week, and almost always by the ninth postmenstrual week [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/11\">",
"       11",
"      </a>",
"      ]. The maternal clearance rate of fetal DNA is extremely rapid; in healthy pregnant women, the half-life is a matter of minutes [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/12\">",
"       12",
"      </a>",
"      ]; therefore, extracted cell-free DNA essentially offers a real-time snapshot of fetal genetic status.",
"      <br/>",
"      <br/>",
"      Fetal DNA typically comprises 10 to 15 percent of the total DNA in maternal circulation during the late first and early second trimesters when prenatal diagnosis is performed [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]. The concentration rises with advancing gestational age and may be as high as 50 percent of the total DNA in the maternal circulation late in gestation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/16\">",
"       16",
"      </a>",
"      ]. Increased amounts of fetal DNA may reflect underlying pregnancy conditions, as discussed below.",
"     </li>",
"     <li>",
"      RNA &mdash; Fetal RNA has been detected as early as the sixth postmenstrual week, and also is cleared rapidly from maternal circulation [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/17\">",
"       17",
"      </a>",
"      ]. Cell-free fetal RNA levels, in contrast to DNA levels, are relatively stable in maternal blood throughout pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     How are fetal nucleic acids distinguished from maternal nucleic acids?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distinguishing maternal from fetal DNA is critical for accurate prenatal diagnosis, but is not always possible. The most reliable method of identifying fetal DNA in the maternal circulation is to identify DNA sequences unique to the Y chromosome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/16,18,19\">",
"     16,18,19",
"    </a>",
"    ], given that normal women don't have a Y chromosome. Another approach is to identify DNA fragments associated with paternally-inherited fetal conditions since these sequences would not be present in the maternal circulation if the mother is unaffected.",
"   </p>",
"   <p>",
"    Examination of maternally-inherited fetal alleles is more problematic. One promising technique is to identify a DNA sequence that is methylated differently in maternal tissue than in fetoplacental tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Maternal-fetal differences in DNA length have also been studied. Although fetal DNA fragments in the maternal circulation are shorter than maternal cell-free DNA fragments, the difference in length is not sufficient to determine whether a DNA fragment isolated from maternal blood is of maternal or fetal origin [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     How are fetal cell-free nucleic acids extracted and evaluated?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most diagnostic and research laboratories amplify and measure the presence and amount of fetal cell-free nucleic acids using real-time quantitative polymerase chain reaction (PCR) technology. PCR works well when the pregnant woman does not have the fetal DNA sequence that is being amplified, such as the Y chromosome or a paternally-inherited autosomal allele.",
"   </p>",
"   <p>",
"    \"Digital PCR\" refers to a technology that runs numerous PCR analyses in parallel and can count the number of target nucleic acids in a sample; it has been studied for use in prenatal diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/23\">",
"     23",
"    </a>",
"    ]. Digital PCR works well in settings in which increased sensitivity is needed, such as finding a rare extra copy of chromosome 21. However, a limitation of this technology is that it requires hundreds or thousands of PCR reactions to be performed simultaneously, and therefore is extremely resource-intensive.",
"   </p>",
"   <p>",
"    Other technical approaches being evaluated include mass spectroscopy of different mRNA alleles (see below); enrichment of fetal DNA using characteristics of fetal DNA fragments that allow it to be isolated and enriched, possibly based on its generally shorter length; and high-throughput genetic sequencing of cell-free DNA in maternal serum that identifies the relative concentration of specific fetal chromosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Researchers have made considerable efforts to avoid false-negative tests caused by a failure to extract fetal nucleic acids from the maternal circulation. One approach to this problem is to take advantage of the differences between methylation patterns of maternal and fetal DNA (genomic regions of DNA from the placenta and maternal blood cells are methylated, or silenced, differently) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/20,26,27\">",
"     20,26,27",
"    </a>",
"    ]. Identification of a hypomethylated fetal DNA \"marker\" serves as a positive control to distinguish a test that fails to identify any fetal DNA at all (ie, false negative) from a test that fails to identify the fetal DNA sequence (ie, true negative) targeted for investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PRENATAL DIAGNOSTIC APPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current clinically-available noninvasive fetal testing is based upon detection of paternally inherited fetal alleles that are not present in the maternal genome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fetal sex determination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining fetal sex is perhaps the most straightforward use of noninvasive fetal testing. Several common DNA sequences specific to the Y chromosome allow for the determination of fetal sex as early as the seventh postmenstrual week, with 100 percent determination by the 10th postmenstrual week [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. PCR testing of maternal blood for these sequences generates the sex determination: if Y chromosome sequences are present, the fetus is male; if absent, the fetus is presumed to be female.",
"   </p>",
"   <p>",
"    Sex determination may be particularly useful as an initial step in the prenatal diagnosis of X-linked diseases, such as hemophilia. In these cases, most maternal carriers who know that their fetus is female do not pursue invasive fetal diagnosis since a female fetus will either be unaffected or an asymptomatic carrier of the mutation. On the other hand, if a male fetus is diagnosed, there is a 50 percent chance he has the disease so invasive testing for prenatal diagnosis should be offered.",
"   </p>",
"   <p>",
"    Sex determination is also useful in the management of pregnancies in which the fetus is at risk for congenital adrenal hyperplasia. Affected female fetuses can develop genital",
"    <span class=\"nowrap\">",
"     ambiguity/genital",
"    </span>",
"    virilization, which can be prevented by administering",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    to the mother throughout pregnancy. If the fetus is known to be male, steroid therapy can be omitted and its associated side effects and complications can be avoided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children\", section on 'Prenatal therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis of noninvasive fetal sex determination using cell-free fetal DNA found that real-time quantitative (RTQ)-PCR outperformed conventional PCR (RTQ-PCR sensitivity and specificity: 96 and 99 percent, respectively; conventional PCR sensitivity and specificity: 94 and 97.3 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/31\">",
"     31",
"    </a>",
"    ]. Sensitivity increased with advancing gestational age:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior to 7 weeks (sensitivity 74.5 percent, specificity 99.1 percent)",
"     </li>",
"     <li>",
"      7 to 12 weeks (sensitivity 94.8 percent, specificity 98.9 percent)",
"     </li>",
"     <li>",
"      13 to 20 weeks (sensitivity 95.5 percent, specificity 99.1 percent)",
"     </li>",
"     <li>",
"      After 20 weeks (sensitivity 99.0 percent, specificity 99.6 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tests on urine were unreliable.",
"   </p>",
"   <p>",
"    Direct-to-consumer marketing via the internet and print media of fetal sex testing services has made tests for fetal sex determination widely available, although the accuracy of tests from unregulated laboratories is questionable [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/32\">",
"     32",
"    </a>",
"    ], and their availability raises important ethical concerns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Rhesus typing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The same approach is used for determining fetal Rh(D) status in Rh(D)-negative women. A noninvasive test for fetal Rh(D) DNA in the maternal circulation is commercially available in the United States, and is widely used in Europe to reduce the need for unnecessary fetal surveillance in isoimmunized Rh(D)-negative women carrying an Rh(D)-negative fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5464?source=see_link&amp;anchor=H23486190#H23486190\">",
"     \"Management of pregnancy complicated by Rhesus (Rh) alloimmunization\", section on 'Cell free fetal DNA testing to determine fetal Rh(D) type'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another application is avoidance of unnecessary prenatal immunoglobulin injections for prevention of isoimmunization in Rh(D)-negative women carrying Rh(D)-negative fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/35\">",
"     35",
"    </a>",
"    ]. The cost effectiveness of this approach has not been determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Single gene disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The noninvasive prenatal diagnosis of single gene disorders is limited to detection of paternally inherited mutations, which would not be present in the maternal genome (assuming the mother is unaffected). However, techniques under study that measure the 'relative mutation dosage' of a particular gene in all cell-free DNA in the maternal bloodstream may help overcome this limitation by assessing the fetal allelic contribution to the maternal DNA pool [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For autosomal dominant conditions, diagnosis depends on the identification of the paternal allele. When the father is affected, a \"positive\" test in maternal blood signifies the presence of the defective paternal allele and an affected fetus (assuming the mother is unaffected). Paternally-inherited autosomal dominant diseases that have been detected using fetal DNA in maternal blood include Huntington disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], myotonic dystrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/39\">",
"     39",
"    </a>",
"    ], and achondroplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the mother is affected by an autosomal dominant disease, noninvasive fetal diagnosis is not possible because fetal nucleic acids derived from maternal alleles cannot be distinguished from maternal nucleic acids.",
"   </p>",
"   <p>",
"    In the case of autosomal recessive conditions where the parents are carriers of different mutations, a \"negative\" test for the paternal mutation rules out an affected fetus. A \"positive\" test indicates that the fetus has inherited the paternal allele carrying the mutation; however, the test cannot distinguish the fetus that is an unaffected carrier of the paternal allele from the fetus that carries the paternal allele as well as a maternal allele, and therefore is affected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Commercial availability",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is less commercial interest in developing tests for fetal genetic disorders using cell-free nucleic acids in maternal circulation than there is for diagnosing aneuploidy, since far more couples desire aneuploidy testing than testing for Mendelian disorders. It is unclear whether noninvasive tests for common single gene disorders such as cystic fibrosis or beta thalassemia will be commercially available in the next few years, although many observers think that their development is inevitable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fetal aneuploidies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, fetal DNA levels in the maternal circulation are increased in trisomy 21 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/41,42\">",
"     41,42",
"    </a>",
"    ] and trisomy 13 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/43\">",
"     43",
"    </a>",
"    ], but not trisomy 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/43\">",
"     43",
"    </a>",
"    ]. The challenge in detecting fetal aneuploidies is to identify an extra (or missing) copy of a fetal chromosome in the maternal blood where fetal DNA constitutes only a small fraction of the cell-free DNA. The amount of chromosome 21, for example, cannot be simply quantified, because a 50 percent increase of fetal chromosome 21 in trisomy 21 (Down syndrome) would be lost in the \"noise\" of background maternal chromosome 21 in the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because fetal DNA gets lost among the more abundant maternal DNA, an alternative strategy is to search for imprinted genes with mRNA transcripts expressed only by placental chromosome 21. The sequence PLAC4 in mRNA is used for this purpose, and a ratio is measured between the quantity of different alleles of the PLAC4 mRNA in circulation. It is assumed that the fetus carries a chromosome 21 from each parent and, therefore, (normal) disomy 21 should generate equal amounts of two alleles of PLAC4 mRNA. A 2:1 or 1:2 ratio suggests trisomy. This approach identified 9 of 10 cases of Down syndrome and excluded 55 of 57 normal controls in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A limitation of this approach is that it only works for fetuses that are heterozygous for the single nucleotide polymorphism (SNP) that is tested. A fetus homozygous for the SNP would generate no ratio (all the SNPs are the same) and therefore a diagnosis could not be made. With the discovery of more SNPs for imprinted genes on chromosome 21, this approach may be useful to a broader proportion of the population.",
"   </p>",
"   <p>",
"    Another promising approach leverages the difference in DNA methylation between maternal and fetal genes. The SERPINB5 gene coding for maspin is hypomethylated in the placenta, but hypermethylated in maternal blood cells. This gene resides on chromosome 18; therefore, an analysis that compares allele ratios among hypomethylated versions of the gene may distinguish the euploid fetus from the fetus with trisomy 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/26,45\">",
"     26,45",
"    </a>",
"    ]. There is some evidence that the same approach may work with differentially-methylated genes on chromosome 21 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &ldquo;Digital PCR\" is being used to count the number of fetal chromosomes 21 of each allele, and therefore can be used to compare the ratio of fetal alleles and diagnose Down syndrome (or other trisomies and monosomies) in heterozygous fetuses. As previously mentioned, this technology is too resource intensive at this time to be cost-effective as a commercial test [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of chromosome-selective sequencing (digital analysis of selected regions [DANSR] assay with a fetal fraction optimized risk of trisomy evaluation [FORTE] algorithm) is another promising evolving technology that has been applied to detection of trisomy 21 and 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. In a high-risk population sampled in the first trimester, the sensitivity of this test for detecting trisomy 21 was 100 percent",
"    <span class=\"nowrap\">",
"     (81/81",
"    </span>",
"    cases); the sensitivity for trisomy 18 was 97.4 percent",
"    <span class=\"nowrap\">",
"     (37/38",
"    </span>",
"    cases), and the specificity for trisomy 21 and 18 was 99.97 percent",
"    <span class=\"nowrap\">",
"     (2887/2888",
"    </span>",
"    cases) and 99.93 percent",
"    <span class=\"nowrap\">",
"     (2886/2888",
"    </span>",
"    cases), respectively, at a cut-off of 1 in 100 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most reliable available technology is massively-parallel sequencing, a technique that sequences short segments of cell-free DNA in the maternal serum and computes a distribution of DNA, both fetal and maternal, in the maternal serum [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/13,25\">",
"     13,25",
"    </a>",
"    ]. A series of validation studies using this technique have demonstrated high sensitivity for diagnosis of Down syndrome (sensitivity 79 to 100 percent, with false positive rates below 1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/13,14,50-52\">",
"     13,14,50-52",
"    </a>",
"    ], trisomy 18 (sensitivity 97 to 100 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/51,52\">",
"     51,52",
"    </a>",
"    ], and trisomy 13 (sensitivity 79 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/52\">",
"     52",
"    </a>",
"    ]. Although there is some evidence that this technique can be used to identify other less common aneuploidies and mosaicisms with similarly high sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/51,52\">",
"     51,52",
"    </a>",
"    ], more research is needed to prove this capacity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link&amp;anchor=H13809396#H13809396\">",
"     \"Overview of prenatal screening and diagnosis of Down syndrome\", section on 'Secondary screening by a maternal plasma based test for fetal DNA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Commercial availability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive screening for aneuploidy using cell-free DNA in the maternal blood was made available for clinical use in 2011 by Sequenom (San Diego, CA), and several other companies launched tests in 2012. Because of the small, but real, risk of a false-positive result, most experts advise using these assays as screening tests, and confirming a positive result with invasive prenatal diagnosis. Furthermore, because most preliminary data came from women at high risk for aneuploidy, the role of these assays in low-risk populations is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pregnancy complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Altered levels of fetal nucleic acids in the maternal circulation are associated with pathologic conditions other than aneuploidy, but these conditions have been the focus of few studies. Circulating levels of cell-free fetal nucleic acids are significantly elevated in placental abruption [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/53\">",
"     53",
"    </a>",
"    ], preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/54-57\">",
"     54-57",
"    </a>",
"    ], preterm labor [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/58\">",
"     58",
"    </a>",
"    ], hyperemesis gravidarum [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/59\">",
"     59",
"    </a>",
"    ], and polyhydramnios [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H197086394\">",
"    <span class=\"h2\">",
"     Multiple gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is minimal information on cell-free DNA levels in multiple gestations; only a few cases have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1448/abstract/51,61\">",
"     51,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Free fetal DNA and RNA can be detected in the maternal circulation in the first trimester; both are cleared rapidly after delivery. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'When are fetal cell-free nucleic acids found in maternal blood?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most noninvasive fetal testing is based upon detection of paternally inherited fetal alleles that are not present in the maternal genome. Fetal nucleic acids derived from maternal alleles cannot be distinguished from maternal nucleic acids. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prenatal diagnostic applications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of noninvasive fetal Rh(D) testing in Rh(D)-negative women allows isoimmunized Rh(D)-negative women to avoid unnecessary fetal surveillance and allows unimmunized Rh(D)-negative women to avoid unnecessary prenatal use of Rh(D) immune globulin. A noninvasive test for fetal Rh(D) DNA in the maternal circulation is commercially available. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Rhesus typing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-invasive fetal sex determination is available from academic and commercial laboratories. This information is useful in fetuses at risk for X-linked diseases or if there is a family history of congenital adrenal hyperplasia (CAH). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Fetal sex determination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-invasive fetal testing for single gene disorders of paternal origin is available from some academic laboratories. Use of this technology is under evaluation, and until more data are available, reliance on these tests may be unwise, particularly given the low overall risk of invasive testing. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Single gene disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of noninvasive testing for trisomy 21, trisomy 18 and trisomy 13 in clinical practice is evolving. Some clinicians are using non-invasive testing as a screening test in high-risk patients, particularly those who would otherwise select invasive diagnostic testing. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Fetal aneuploidies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/1\">",
"      Bianchi DW, Williams JM, Sullivan LM, et al. PCR quantitation of fetal cells in maternal blood in normal and aneuploid pregnancies. Am J Hum Genet 1997; 61:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/2\">",
"      Hamada H, Arinami T, Kubo T, et al. Fetal nucleated cells in maternal peripheral blood: frequency and relationship to gestational age. Hum Genet 1993; 91:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/3\">",
"      Bianchi DW, Zickwolf GK, Weil GJ, et al. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc Natl Acad Sci U S A 1996; 93:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/4\">",
"      Sekizawa A, Samura O, Zhen DK, et al. Apoptosis in fetal nucleated erythrocytes circulating in maternal blood. Prenat Diagn 2000; 20:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/5\">",
"      Tjoa ML, Cindrova-Davies T, Spasic-Boskovic O, et al. Trophoblastic oxidative stress and the release of cell-free feto-placental DNA. Am J Pathol 2006; 169:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/6\">",
"      Lui YY, Chik KW, Chiu RW, et al. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 2002; 48:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/7\">",
"      Lo YM, Lo ES, Watson N, et al. Two-way cell traffic between mother and fetus: biologic and clinical implications. Blood 1996; 88:4390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/8\">",
"      Zhong XY, Holzgreve W, Hahn S. Cell-free fetal DNA in the maternal circulation does not stem from the transplacental passage of fetal erythroblasts. Mol Hum Reprod 2002; 8:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/9\">",
"      Wataganara T, LeShane ES, Chen AY, et al. Plasma gamma-globin gene expression suggests that fetal hematopoietic cells contribute to the pool of circulating cell-free fetal nucleic acids during pregnancy. Clin Chem 2004; 50:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/10\">",
"      Wataganara T, Leshane ES, Chen AY, et al. Circulating cell-free fetal nucleic acid analysis may be a novel marker of fetomaternal hemorrhage after elective first-trimester termination of pregnancy. Ann N Y Acad Sci 2004; 1022:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/11\">",
"      Guibert J, Benachi A, Grebille AG, et al. Kinetics of SRY gene appearance in maternal serum: detection by real time PCR in early pregnancy after assisted reproductive technique. Hum Reprod 2003; 18:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/12\">",
"      Lo YM, Zhang J, Leung TN, et al. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999; 64:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/13\">",
"      Chiu RW, Akolekar R, Zheng YW, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 2011; 342:c7401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/14\">",
"      Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011; 13:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/15\">",
"      Nygren AO, Dean J, Jensen TJ, et al. Quantification of fetal DNA by use of methylation-based DNA discrimination. Clin Chem 2010; 56:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/16\">",
"      Lo YM, Tein MS, Lau TK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998; 62:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/17\">",
"      Chiu RW, Lui WB, Cheung MC, et al. Time profile of appearance and disappearance of circulating placenta-derived mRNA in maternal plasma. Clin Chem 2006; 52:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/18\">",
"      Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/19\">",
"      Honda H, Miharu N, Ohashi Y, Ohama K. Successful diagnosis of fetal gender using conventional PCR analysis of maternal serum. Clin Chem 2001; 47:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/20\">",
"      Poon LL, Leung TN, Lau TK, et al. Differential DNA methylation between fetus and mother as a strategy for detecting fetal DNA in maternal plasma. Clin Chem 2002; 48:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/21\">",
"      Papageorgiou EA, Karagrigoriou A, Tsaliki E, et al. Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. Nat Med 2011; 17:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/22\">",
"      Chan KC, Zhang J, Hui AB, et al. Size distributions of maternal and fetal DNA in maternal plasma. Clin Chem 2004; 50:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/23\">",
"      Lo YM, Lun FM, Chan KC, et al. Digital PCR for the molecular detection of fetal chromosomal aneuploidy. Proc Natl Acad Sci U S A 2007; 104:13116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/24\">",
"      Li Y, Di Naro E, Vitucci A, et al. Detection of paternally inherited fetal point mutations for beta-thalassemia using size-fractionated cell-free DNA in maternal plasma. JAMA 2005; 293:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/25\">",
"      Chiu RW, Chan KC, Gao Y, et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci U S A 2008; 105:20458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/26\">",
"      Chim SS, Tong YK, Chiu RW, et al. Detection of the placental epigenetic signature of the maspin gene in maternal plasma. Proc Natl Acad Sci U S A 2005; 102:14753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/27\">",
"      Chim SS, Jin S, Lee TY, et al. Systematic search for placental DNA-methylation markers on chromosome 21: toward a maternal plasma-based epigenetic test for fetal trisomy 21. Clin Chem 2008; 54:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/28\">",
"      Stanghellini I, Bertorelli R, Capone L, et al. Quantitation of fetal DNA in maternal serum during the first trimester of pregnancy by the use of a DAZ repetitive probe. Mol Hum Reprod 2006; 12:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/29\">",
"      Scheffer PG, van der Schoot CE, Page-Christiaens GC, et al. Reliability of fetal sex determination using maternal plasma. Obstet Gynecol 2010; 115:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/30\">",
"      Akolekar R, Farkas DH, VanAgtmael AL, et al. Fetal sex determination using circulating cell-free fetal DNA (ccffDNA) at 11 to 13 weeks of gestation. Prenat Diagn 2010; 30:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/31\">",
"      Devaney SA, Palomaki GE, Scott JA, Bianchi DW. Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis. JAMA 2011; 306:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/32\">",
"      Bianchi DW. At-home fetal DNA gender testing: caveat emptor. Obstet Gynecol 2006; 107:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/33\">",
"      Gautier E, Benachi A, Giovangrandi Y, et al. Fetal RhD genotyping by maternal serum analysis: a two-year experience. Am J Obstet Gynecol 2005; 192:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/34\">",
"      Finning K, Martin P, Daniels G. A clinical service in the UK to predict fetal Rh (Rhesus) D blood group using free fetal DNA in maternal plasma. Ann N Y Acad Sci 2004; 1022:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/35\">",
"      Finning K, Martin P, Summers J, et al. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ 2008; 336:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/36\">",
"      Lun FM, Tsui NB, Chan KC, et al. Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and relative mutation dosage on DNA in maternal plasma. Proc Natl Acad Sci U S A 2008; 105:19920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/37\">",
"      Gonz&aacute;lez-Gonz&aacute;lez MC, Trujillo MJ, Rodr&iacute;guez de Alba M, et al. Huntington disease-unaffected fetus diagnosed from maternal plasma using QF-PCR. Prenat Diagn 2003; 23:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/38\">",
"      Bustamante-Aragones A, Trujillo-Tiebas MJ, Gallego-Merlo J, et al. Prenatal diagnosis of Huntington disease in maternal plasma: direct and indirect study. Eur J Neurol 2008; 15:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/39\">",
"      Amicucci P, Gennarelli M, Novelli G, Dallapiccola B. Prenatal diagnosis of myotonic dystrophy using fetal DNA obtained from maternal plasma. Clin Chem 2000; 46:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/40\">",
"      Saito H, Sekizawa A, Morimoto T, et al. Prenatal DNA diagnosis of a single-gene disorder from maternal plasma. Lancet 2000; 356:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/41\">",
"      Lo YM, Lau TK, Zhang J, et al. Increased fetal DNA concentrations in the plasma of pregnant women carrying fetuses with trisomy 21. Clin Chem 1999; 45:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/42\">",
"      Zhong XY, B&uuml;rk MR, Troeger C, et al. Fetal DNA in maternal plasma is elevated in pregnancies with aneuploid fetuses. Prenat Diagn 2000; 20:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/43\">",
"      Wataganara T, LeShane ES, Farina A, et al. Maternal serum cell-free fetal DNA levels are increased in cases of trisomy 13 but not trisomy 18. Hum Genet 2003; 112:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/44\">",
"      Lo YM, Tsui NB, Chiu RW, et al. Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection. Nat Med 2007; 13:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/45\">",
"      Tong YK, Ding C, Chiu RW, et al. Noninvasive prenatal detection of fetal trisomy 18 by epigenetic allelic ratio analysis in maternal plasma: Theoretical and empirical considerations. Clin Chem 2006; 52:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/46\">",
"      Fan HC, Quake SR. Detection of aneuploidy with digital polymerase chain reaction. Anal Chem 2007; 79:7576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/47\">",
"      Ashoor G, Syngelaki A, Wagner M, et al. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 206:322.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/48\">",
"      Sparks AB, Struble CA, Wang ET, et al. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 206:319.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/49\">",
"      Norton ME, Brar H, Weiss J, et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012; 207:137.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/50\">",
"      Ehrich M, Deciu C, Zwiefelhofer T, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011; 204:205.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/51\">",
"      Sehnert AJ, Rhees B, Comstock D, et al. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. Clin Chem 2011; 57:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/52\">",
"      Bianchi DW, Platt LD, Goldberg JD, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012; 119:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/53\">",
"      Lau TK, Lo KW, Chan LY, et al. Cell-free fetal deoxyribonucleic acid in maternal circulation as a marker of fetal-maternal hemorrhage in patients undergoing external cephalic version near term. Am J Obstet Gynecol 2000; 183:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/54\">",
"      Lo YM, Leung TN, Tein MS, et al. Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem 1999; 45:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/55\">",
"      Zhong XY, Laivuori H, Livingston JC, et al. Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia. Am J Obstet Gynecol 2001; 184:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/56\">",
"      Sifakis S, Zaravinos A, Maiz N, et al. First-trimester maternal plasma cell-free fetal DNA and preeclampsia. Am J Obstet Gynecol 2009; 201:472.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/57\">",
"      Illanes S, Parra M, Serra R, et al. Increased free fetal DNA levels in early pregnancy plasma of women who subsequently develop preeclampsia and intrauterine growth restriction. Prenat Diagn 2009; 29:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/58\">",
"      Leung TN, Zhang J, Lau TK, et al. Maternal plasma fetal DNA as a marker for preterm labour. Lancet 1998; 352:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/59\">",
"      Sugito Y, Sekizawa A, Farina A, et al. Relationship between severity of hyperemesis gravidarum and fetal DNA concentration in maternal plasma. Clin Chem 2003; 49:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/60\">",
"      Zhong XY, Holzgreve W, Li JC, et al. High levels of fetal erythroblasts and fetal extracellular DNA in the peripheral blood of a pregnant woman with idiopathic polyhydramnios: case report. Prenat Diagn 2000; 20:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1448/abstract/61\">",
"      Ohashi Y, Miharu N, Honda H, et al. Quantitation of fetal DNA in maternal serum in normal and aneuploid prenancies. Hum Genet 2001; 108:123.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 458 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-188.40.116.55-6D8648E745-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_26_1448=[""].join("\n");
var outline_f1_26_1448=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Where do fetal cell-free nucleic acids come from?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      When are fetal cell-free nucleic acids found in maternal blood?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      How are fetal nucleic acids distinguished from maternal nucleic acids?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      How are fetal cell-free nucleic acids extracted and evaluated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PRENATAL DIAGNOSTIC APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fetal sex determination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Rhesus typing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Single gene disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Commercial availability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fetal aneuploidies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Commercial availability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pregnancy complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H197086394\">",
"      Multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5464?source=related_link\">",
"      Management of pregnancy complicated by Rhesus (Rh) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=related_link\">",
"      Overview of prenatal screening and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31754?source=related_link\">",
"      Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_26_1449="Diagnosis and treatment of histoplasmosis in HIV-infected patients";
var content_f1_26_1449=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of histoplasmosis in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/26/1449/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1449/contributors\">",
"     John W Baddley, MD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/26/1449/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1449/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/26/1449/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1449/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/26/1449/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histoplasmosis is an important infectious disease among patients with AIDS and continues to cause severe morbidity and mortality in endemic areas, particularly in resource-limited settings.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of histoplasmosis will be discussed here. The epidemiology and clinical manifestations of infection are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39924?source=see_link\">",
"     \"Epidemiology and clinical manifestations of histoplasmosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple diagnostic tests for disseminated H. capsulatum infection, including culture, serology, antigen testing, and direct microscopy; the diagnostic yield will depend on the stage of disease. Since most AIDS patients have disseminated disease, the most sensitive and specific test is detection of histoplasma antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When resources are limited, the simplest and least expensive test (although not definitive) is direct microscopy of budding yeast within tissues or body fluids. The combination of culture with direct microscopy increases the diagnostic yield.",
"   </p>",
"   <p>",
"    Timely diagnosis requires a high index of clinical suspicion. The advantages and disadvantages of these methods for diagnosis of histoplasmosis in the HIV-infected patient are discussed below. Additional information on diagnostic testing for histoplasmosis can also be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9321?source=see_link\">",
"     \"Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antigen detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histoplasma antigen (HPA) detection is a sensitive diagnostic method for disseminated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], although it is usually unavailable in resource-limited settings. Antigen detection can be performed on samples of urine, serum, cerebrospinal fluid, and bronchoalveolar lavage fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/2\">",
"     2",
"    </a>",
"    ]. In one report, HPA was detected in AIDS patients with disseminated histoplasmosis in the following samples: urine (97 percent), blood (83 percent), and cerebrospinal fluid (67 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/4\">",
"     4",
"    </a>",
"    ]. In another report, antigen testing was positive in 39 of 40 HIV-infected patients in urine and 36 of 37 patients in serum [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even though the results of HPA testing may not be immediately available, levels should be sent if histoplasmosis is suspected, since they are useful in monitoring disease activity. HPA levels decline in response to treatment, with serum HPA levels declining more rapidly than urine HPA levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culture of blood, respiratory samples, or other tissues (eg, bone marrow) remains the \"gold standard\" for diagnosis; however, cultures of H. capsulatum may take up to four to six weeks and sensitivity will depend on disease burden [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/5\">",
"     5",
"    </a>",
"    ]. In one retrospective study of 46 HIV-infected patients with disseminated disease, isolator blood cultures were positive in 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic yield of sputum in the AIDS population has not been well studied. Sputum culture has been reported to be positive in 34 percent of non-AIDS patients with pulmonary histoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/6\">",
"     6",
"    </a>",
"    ]. The reported diagnostic yield of bronchoalveolar lavage (BAL) in AIDS patients has varied, but one small study of 27 patients found the sensitivity of BAL on stain and culture to be 70 percent and 89 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory personnel involved with Histoplasma cultures should use appropriate procedures to prevent exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Direct microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis can be rapidly made by visualization of the organism within cells on a Wright's stained smear of either peripheral blood or a buffy coat. This method allows rapid identification and is very inexpensive, although the sensitivity is low (less than 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Bone marrow, bronchial, and lymph node aspirates can also be stained with Wright, Giemsa, or May-Gr&uuml;nwald-Giemsa; this inexpensive method is particularly useful in some endemic resource-limited areas [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/5\">",
"     5",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef75209 graphicRef74406 graphicRef65482 \" href=\"UTD.htm?23/62/24553\">",
"     picture 1A-C",
"    </a>",
"    ). H. capsulatum can be confused with Candida glabrata, Penicillium marneffei, and amastigote forms of Trypanosoma cruzi [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A combination of culture and direct microscopy can be additive in diagnostic sensitivity. In a study of 36 patients with AIDS and suspected disseminated disease, the combination of blood culture plus examination of the peripheral smear by direct microscopy had a sensitivity of 88 percent for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/8\">",
"     8",
"    </a>",
"    ]. In AIDS patients with disseminated disease and with negative blood smears, bone marrow aspiration with direct staining is an equally sensitive method for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The advantage of direct microscopic examination is that a positive result enables rapid initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=see_link\">",
"     \"Diagnosis and treatment of pulmonary histoplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathologic examination of tissues using special stains, such as periodic acid-Schiff or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/57/3989?source=see_link\">",
"     methenamine",
"    </a>",
"    silver, requires additional facilities and a pathologist. Tissue preparation leads to a delay in diagnosis and sensitivity is similar to direct microscopy. Sites for sampling include bone marrow, lymph nodes, and skin and mucosal lesions, if present. Laboratory evidence of granulomas with yeasts resembling Histoplasma in extrapulmonary tissues is consistent with disseminated disease (",
"    <a class=\"graphic graphic_picture graphicRef68444 \" href=\"UTD.htm?30/44/31427\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard serology, consisting of either complement fixation or immunodiffusion, has a combined diagnostic yield of approximately 70 percent in patients with AIDS and histoplasmosis. However, since results are often delayed for two to six weeks, serologic tests are of limited value in the initial diagnosis of histoplasmosis. Non-reactive serologic testing has also been described in HIV-infected patients with disseminated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunodiffusion is less sensitive but more specific than complement fixation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/5\">",
"     5",
"    </a>",
"    ]. Although no specific titer has been found to indicate disease activity, titers of at least 1:8 by complement fixation are present in 70 percent of patients with active infection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive skin test to histoplasmin is not predictive of active disease. Skin testing is rarely useful diagnostically and should not be routinely performed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/12\">",
"     12",
"    </a>",
"    ]. However, skin testing has proven useful in epidemiologic studies aimed at identifying areas of endemicity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculosis is the leading pathogen to consider in the differential diagnosis of histoplasmosis. Often, in fact, tuberculosis infection and histoplasmosis can co-exist in the same patient in certain endemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/5\">",
"     5",
"    </a>",
"    ]. Therefore, patient management should include a diagnostic evaluation for both infections. Pneumocystis is another leading diagnostic consideration due to the common radiographic appearance of diffuse infiltrates.",
"   </p>",
"   <p>",
"    Since HIV-infected patients with histoplasmosis have advanced immunosuppression, they are often concurrently infected with other opportunistic pathogens, supporting the need for a careful search for coinfections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid initiation of therapy is indicated due to the high mortality of disseminated disease. Treatment involves an acute phase of induction therapy, followed by long-term maintenance [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment approaches should be categorized on the basis of immune function and severity of illness:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with severe immunosuppression, disseminated disease, sepsis-like syndromes, high fever, clinical instability, or findings such as respiratory failure, other organ dysfunction, or pancytopenia should be classified as having moderately severe to severe disease. Treatment of severe disease requires an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      formulation as the front-line agent.",
"     </li>",
"     <li>",
"      Patients with mild clinical symptoms and a single focus of disease (other than the CNS) have mild to moderate disease and can receive initial",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In order to prevent relapse, suppressive therapy is indicated in patients who remain highly immunosuppressed. Maintenance therapy and treatment of mild to moderate disease are best managed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , which has better in vitro activity than other oral azole agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ). Itraconazole was also found to be superior for induction therapy of histoplasmosis with overall lower mortality compared with historical controls who were given fluconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/15\">",
"     15",
"    </a>",
"    ]. Use of fluconazole also led to high rates of relapse during maintenance therapy, consistent with its lower in vitro activity [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Details of therapeutic management and discussion of available antifungal agents follow below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antifungal agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most active agents for the treatment of histoplasmosis include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    . Amphotericin B is usually used for induction therapy and oral itraconazole is used for consolidation therapy and long-term suppression.",
"   </p>",
"   <p>",
"    Guidelines for the treatment of histoplasmosis were published by the Infectious Diseases Society of America in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/10\">",
"     10",
"    </a>",
"    ]; an overview of the treatment of histoplasmosis in immunocompetent hosts is discussed elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/10\">",
"     10",
"    </a>",
"    ]. Treatment of the HIV-infected patient with progressive disseminated histoplasmosis is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    is considered first-line therapy for AIDS patients with severe disseminated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/10,16\">",
"     10,16",
"    </a>",
"    ] and for patients with CNS involvement because it is fungicidal and leads to faster clearance of fungemia compared with the fungistatic dug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    . [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/17\">",
"     17",
"    </a>",
"    ]. Also, several days of a loading dose are required for the levels of itraconazole to reach steady state. The disadvantages of amphotericin B preparations are requirements for a central venous catheter and nephrotoxicity associated with the deoxycholate formulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Itraconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    is the preferred oral azole for histoplasmosis due to its overall better in vitro activity compared with other azoles, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/18\">",
"     18",
"    </a>",
"    ]. Small case series have suggested excellent clinical activity of itraconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/19\">",
"     19",
"    </a>",
"    ]; in one review of 12 AIDS patients with disseminated disease, 11 patients responded to itraconazole [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/20\">",
"     20",
"    </a>",
"    ]. Furthermore, the development of resistance to itraconazole during therapy has not been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    is not as active in vitro against H. capsulatum as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and leads to slower clearance of fungemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/18\">",
"     18",
"    </a>",
"    ]. For example, in one study, a significantly higher proportion of patients cleared fungemia after four weeks of therapy in the itraconazole arm than in the fluconazole arm (92 versus 62 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a multicenter, open-label, nonrandomized prospective trial of 49 HIV-infected patients with mild or moderately severe histoplasmosis, more than one-quarter had progression of disease on induction therapy and approximately one-third relapsed despite maintenance therapy with 400 mg of daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/15\">",
"     15",
"    </a>",
"    ]. Furthermore, in 10 of 17 patients for whom there were paired pretreatment and failure or relapse isolates available, at least a fourfold increase in the minimal inhibitory concentration (MIC) for fluconazole was demonstrated consistent with the development of resistance during fluconazole therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of other azoles, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    or echinocandins, is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of newer azoles, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , is unclear since these have not been studied in patients with AIDS; however, both have good in vitro activity against Histoplasma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9321?source=see_link\">",
"     \"Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence to support a role for the use of echinocandins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Moderately severe to severe disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated histoplasmosis in the HIV-infected host is fatal without therapeutic intervention. A double-blind multicenter trial assigned 81 AIDS patients with moderately severe and severe disseminated histoplasmosis in a 2:1 randomization scheme to either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    (3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily) or deoxycholate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    (0.7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily) for a 14-day induction phase [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients with a clinical response to therapy were then switched to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    . Baseline blood cultures were positive in 74 percent of the patients. The trial demonstrated the following significant results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Response rates (as measured by improvement in clinical symptoms such as fever) were higher in patients assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      (88 versus 64 percent).",
"     </li>",
"     <li>",
"      After two weeks of therapy, there was no significant difference in the time to negative cultures in either arm.",
"     </li>",
"     <li>",
"      However, patient survival was significantly higher in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      . One of 53 patients (2 percent) in the liposomal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      arm died of bacterial sepsis while 3 of 24 (13 percent) in the deoxycholate arm died of disseminated histoplasmosis.",
"     </li>",
"     <li>",
"      Nephrotoxicity was more common in the deoxycholate arm (37 versus 9 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limitations of the above trial include the dosing regimen of deoxycholate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    of only 0.7",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    Other lipid formulations of AmB (dosed at 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily) or deoxycholate AmB (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily) are considered alternatives if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    is not available or if the cost is prohibitive. Deoxycholate amphotericin B is an alternative in patients at low risk of nephrotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2009 CDC, National Institutes of Health, and HIV Medicine Association Guidelines recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    as initial treatment for HIV-infected patients with moderately severe to severe disease due to its greater efficacy, lower toxicity, and better overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/1,10\">",
"     1,10",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef82973 \" href=\"UTD.htm?1/36/1613\">",
"     table 1",
"    </a>",
"    ). Treatment should continue for two weeks or greater duration (or until clinical improvement).",
"   </p>",
"   <p>",
"    After one to two weeks of induction therapy, patients can be switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    as \"step down\" therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/24\">",
"     24",
"    </a>",
"    ]. A loading dose of 200 mg three times daily for three days is followed by maintenance doses of 200 mg twice daily thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/1\">",
"     1",
"    </a>",
"    ]. Itraconazole solution is preferred rather than capsules due to better absorption. A detailed discussion of drug interactions and food requirements is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Mild to moderate disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    is not required in HIV-infected patients with mild to moderate disease severity and non-meningeal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/17,25\">",
"     17,25",
"    </a>",
"    ]. In a multicenter open-label study of 59 patients with disseminated histoplasmosis without meningeal involvement,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    led to resolution of clinical symptoms in 85 percent of cases after 12 weeks of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/17\">",
"     17",
"    </a>",
"    ]. However, patients with more severe disease at baseline (fever &gt;39.5&ordm; Celsius or Karnofsky score &lt;60) or laboratory abnormalities (alkaline phosphatase &gt;5 times normal or albumin &lt;3",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    tended to respond more poorly than did other patients. These data suggest that patients with severe disease at baseline should undergo induction therapy with amphotericin B.",
"   </p>",
"   <p>",
"    For AIDS patients with progressive, disseminated histoplasmosis, at least 12 weeks of therapy is required for mild, moderate, or severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    for initial therapy for patients with fungemia, or other evidence of disseminated infection, since sterilization of blood cultures is slower with this fungistatic agent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there are no direct comparative studies, the data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is not as active against Histoplasma as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and should not be used as first-line therapy for even mild or moderate disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/15\">",
"     15",
"    </a>",
"    ]. In one multicenter open-label study, 36 patients with mild to moderate disseminated histoplasmosis received fluconazole (800 mg daily); seven patients failed induction therapy with fluconazole and one patient died. Furthermore, of 36 patients who entered into the one-year maintenance phase of the study, one-third of the patients relapsed.",
"   </p>",
"   <p>",
"    A subsequent study demonstrated that patients with microbiologic failure on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    had developed drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/22\">",
"     22",
"    </a>",
"    ]. There was at least a fourfold increase in fluconazole minimal inhibitory concentration (MIC) in the isolates from 10 of 17 patients for whom paired pretreatment and post-treatment isolates were available. Cross-resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    was not found among these isolates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no therapeutic trials evaluating treatment regimens for CNS histoplasmosis. We agree with the IDSA and CDC recommendations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily) for a total of 175",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (given over four to six weeks) followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200 mg two to three times daily) for a minimum of one year or until resolution of CSF abnormalities (including serum and CNS histoplasma antigen) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. We prefer three times daily administration of itraconazole due to its poor penetration into the CNS.",
"   </p>",
"   <p>",
"    A study of mainly AIDS patients with a variety of fungal CNS infections reported one patient who was refractory to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    who subsequently responded to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful assessment for possible drug interactions with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    use is recommended. Adverse events due to itraconazole are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concomitant administration of nephrotoxic drugs with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    is discouraged, whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial course of therapy should be at least one year for PDH. Treatment should continue until clinical symptoms have resolved. Prompt initiation of ART is recommended, if available.",
"   </p>",
"   <p>",
"    Life-long suppressive therapy may be necessary for HIV-infected patients who do not achieve immune recovery on ART due to the risk of relapse. Furthermore, those patients who experience relapse after completion of the initial course of therapy should be considered for lifelong prophylaxis, regardless of whether successful immune recovery has occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Suppressive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MONITORING OF PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to frequent clinical follow-up, antigen levels should be assayed quarterly during therapy to assess treatment response [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/1\">",
"     1",
"    </a>",
"    ]. Antigen levels should also be attained for 6 to12 months after completion of therapy to determine early signs of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antigen monitoring during suppressive therapy is not routinely recommended, but should be considered if relapse is suspected based on clinical symptoms, or if CD4 cell counts decline to less than 100",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    Increases in HPA of at least two radioimmunoassay units in the urine or blood have been found to indicate relapse, even before clinical relapse is detected [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    are also recommended to determine adequacy of drug exposure, particularly in light of potential drug interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The serum concentration should be &gt;1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    ideally drawn as a trough level after seven days on the current regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     IMMUNE RECONSTITUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;ART leads to restoration of T cell immunity, which is an important mediator of defense against histoplasmosis. Immune reconstitution can sometimes complicate treatment of other opportunistic infections; however, immune reconstitution inflammatory syndrome has been uncommonly reported in the setting of disseminated histoplasmosis. In a series of four patients with disseminated histoplasmosis, immune reconstitution led to clinical presentations of liver abscesses, compressive lymphadenitis, intestinal obstruction, uveitis and arthritis within a median of 45 days after initiation of potent ART [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, one study suggested that patients who were also taking ART had better overall treatment outcomes for histoplasmosis as well [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/31\">",
"     31",
"    </a>",
"    ]. Thus, ART should not be withheld due to concerns regarding the immune reconstitution inflammatory syndrome. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Morbidity and mortality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As the ART rollout in resource-limited settings continues, more information will be available regarding the prevalence of this complication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     MORBIDITY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the era of highly active antiretroviral therapy, morbidity and mortality secondary to disseminated histoplasmosis remains high in patients who are not taking ART or who have multi-drug resistant HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/2\">",
"     2",
"    </a>",
"    ]. A retrospective study was performed in 46 HIV-infected patients who were diagnosed with histoplasmosis from 1999 to 2006, 93 percent of whom had disseminated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/2\">",
"     2",
"    </a>",
"    ]. Histoplasmosis was the first manifestation of HIV infection in approximately one-quarter of the patients. Among those with previously diagnosed HIV infection, only 21 percent were taking ART and none had viral suppression at the time of diagnosis. At the three-month follow-up, 39 percent of the patients had died.",
"   </p>",
"   <p>",
"    Disseminated histoplasmosis is also an important cause of death in resource-limited settings where the vast majority of patients present with advanced untreated HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/5,32\">",
"     5,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients with disseminated histoplasmosis who present with severe respiratory and renal impairment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fungemia have a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. In one retrospective study of 378 HIV-infected patients in Brazil, the mortality in patients with disseminated histoplasmosis (n = 164) was higher than in those with other opportunistic infections (32 versus 14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/33\">",
"     33",
"    </a>",
"    ]. In one study from Europe, autopsy data in 13 AIDS patients confirmed the widespread disseminated nature of histoplasmosis in this patient population with a median of 4.5 organs involved [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory markers that have been associated with poor clinical outcome include elevated lactate dehydrogenase, elevated creatinine, thrombocytopenia, anemia, and hypoalbuminemia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUPPRESSIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fifty to 80 percent of patients with histoplasmosis and AIDS will relapse if prolonged, suppressive therapy is not continued [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/35\">",
"     35",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    prevents relapse in up to 95 percent of cases and should be administered continually after completion of one-year maintenance therapy if immunosuppression has not reversed with ART [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, data suggest that suppressive therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    may be discontinued safely if patients fulfill the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Completion of a minimum of one-year maintenance therapy",
"     </li>",
"     <li>",
"      Histoplasma antigen levels are negative or remain low (&lt;2",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"     </li>",
"     <li>",
"      Blood cultures are negative",
"     </li>",
"     <li>",
"      CD4 cell counts have increased to &gt;150",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      and the patient remains on ART [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1449/abstract/24,37,38\">",
"       24,37,38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, suppressive therapy should be resumed if the patient discontinues ART or if their CD4 cell count begins to decline to &lt;150",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PRIMARY PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prevention of histoplasmosis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/5/13393?source=see_link\">",
"       \"Patient information: Histoplasmosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histoplasmosis is an important cause of morbidity and mortality in patients living in endemic areas who are not taking antiretroviral therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most sensitive diagnostic method for disseminated disease is detection of histoplasma antigen, although this is usually not available in resource-limited settings. The simplest and least expensive test is direct microscopy. A combination of culture and direct microscopy are diagnostic in the vast majority of AIDS patients with disseminated disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tuberculosis and pneumocystosis are the leading pathogens to consider in the differential of histoplasmosis; a diagnostic work-up should include evaluation for both infections. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe progressive disseminated histoplasmosis, we recommend induction therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      (3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily) for one to two weeks (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We also recommend maintenance therapy for a minimum of one year to prevent relapse (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We prefer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      (200 mg three times daily for three days followed by 200 mg twice daily) for maintenance therapy due to its excellent activity against histoplasma in comparison with other azoles. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      formulations are acceptable for induction therapy if",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      is not available or is prohibitively expensive. However, for induction therapy, we do NOT recommend use of alternative agents to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      ) unless drug interactions are a major consideration. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For AIDS patients with mild to moderate nonmeningeal disease, we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      (200 mg three times daily for three days followed by 200 mg twice daily) for a minimum of one year (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients with central nervous system disease, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily) for a total of 175",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (given over four to six weeks) for induction therapy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      (200 mg three times daily) for maintenance therapy for a minimum of one year and until resolution of CSF abnormalities.",
"     </li>",
"     <li>",
"      ART should be initiated as soon as possible to improve cellular immunity. Lifelong maintenance therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      may be needed in patients who do not achieve immune recovery on ART. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to frequent clinical follow-up, antigen levels should be assayed during therapy to assess treatment response. For patients on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      , serum levels should also be monitored. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Monitoring of patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected patients with disseminated histoplasmosis who present with severe respiratory and renal impairment",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fungemia have a poor prognosis. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Morbidity and mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Secondary prophylaxis should be administered until immune recovery (CD4 cell count greater than 150",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      has been attained. Then secondary prophylaxis can be discontinued if the patient has no laboratory evidence of ongoing infection. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Suppressive therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/1\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/2\">",
"      Baddley JW, Sankara IR, Rodriquez JM, et al. Histoplasmosis in HIV-infected patients in a southern regional medical center: poor prognosis in the era of highly active antiretroviral therapy. Diagn Microbiol Infect Dis 2008; 62:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/3\">",
"      Hage CA, Ribes JA, Wengenack NL, et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis 2011; 53:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/4\">",
"      Wheat LJ, Connolly-Stringfield PA, Baker RL, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990; 69:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/5\">",
"      Couppi&eacute; P, Aznar C, Carme B, Nacher M. American histoplasmosis in developing countries with a special focus on patients with HIV: diagnosis, treatment, and prognosis. Curr Opin Infect Dis 2006; 19:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/6\">",
"      Joseph Wheat L. Current diagnosis of histoplasmosis. Trends Microbiol 2003; 11:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/7\">",
"      Prechter GC, Prakash UB. Bronchoscopy in the diagnosis of pulmonary histoplasmosis. Chest 1989; 95:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/8\">",
"      Nightingale SD, Parks JM, Pounders SM, et al. Disseminated histoplasmosis in patients with AIDS. South Med J 1990; 83:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/9\">",
"      Akpek G, Lee SM, Gagnon DR, et al. Bone marrow aspiration, biopsy, and culture in the evaluation of HIV-infected patients for invasive mycobacteria and histoplasma infections. Am J Hematol 2001; 67:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/10\">",
"      Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/11\">",
"      Wheat LJ, Connolly-Stringfield P, Blair R, et al. Histoplasmosis relapse in patients with AIDS: detection using Histoplasma capsulatum variety capsulatum antigen levels. Ann Intern Med 1991; 115:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/12\">",
"      Hajjeh RA. Disseminated histoplasmosis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 Suppl 1:S108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/13\">",
"      Edwards LB, Acquaviva FA, Livesay VT, et al. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis 1969; 99:Suppl:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/14\">",
"      Gasc&oacute;n J, Torres JM, Jim&eacute;nez M, et al. Histoplasmosis infection in Spanish travelers to Latin America. Eur J Clin Microbiol Infect Dis 2005; 24:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/15\">",
"      Wheat J, MaWhinney S, Hafner R, et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. Am J Med 1997; 103:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/16\">",
"      Lanternier F, Lortholary O. Liposomal amphotericin B: what is its role in 2008? Clin Microbiol Infect 2008; 14 Suppl 4:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/17\">",
"      Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med 1995; 98:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/18\">",
"      Wheat LJ, Connolly P, Haddad N, et al. Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrob Agents Chemother 2002; 46:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/19\">",
"      Sarosi GA, Johnson PC. Disseminated histoplasmosis in patients infected with human immunodeficiency virus. Clin Infect Dis 1992; 14 Suppl 1:S60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/20\">",
"      Hostetler JS, Denning DW, Stevens DA. US experience with itraconazole in Aspergillus, Cryptococcus and Histoplasma infections in the immunocompromised host. Chemotherapy 1992; 38 Suppl 1:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/21\">",
"      Brooks JT, Wheat LJ. Histoplasmosis: update 1998. AIDS Clin Care 1998; 10:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/22\">",
"      Wheat LJ, Connolly P, Smedema M, et al. Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clin Infect Dis 2001; 33:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/23\">",
"      Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002; 137:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/24\">",
"      Wheat J. Histoplasmosis. Experience during outbreaks in Indianapolis and review of the literature. Medicine (Baltimore) 1997; 76:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/25\">",
"      Dismukes WE, Bradsher RW Jr, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med 1992; 93:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/26\">",
"      Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/27\">",
"      Wheat LJ, Connolly-Stringfield P, Williams B, et al. Diagnosis of histoplasmosis in patients with the acquired immunodeficiency syndrome by detection of Histoplasma capsulatum polysaccharide antigen in bronchoalveolar lavage fluid. Am Rev Respir Dis 1992; 145:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/28\">",
"      Huet E, Hadji C, Hulin A, et al. Therapeutic monitoring is necessary for the association itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis. AIDS 2008; 22:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/29\">",
"      Koo HL, Hamill RJ, Andrade RA. Drug-drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis. Clin Infect Dis 2007; 45:e77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/30\">",
"      Breton G, Adle-Biassette H, Therby A, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. AIDS 2006; 20:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/31\">",
"      Tob&oacute;n AM, Agudelo CA, Rosero DS, et al. Disseminated histoplasmosis: a comparative study between patients with acquired immunodeficiency syndrome and non-human immunodeficiency virus-infected individuals. Am J Trop Med Hyg 2005; 73:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/32\">",
"      Huber F, Nacher M, Aznar C, et al. AIDS-related Histoplasma capsulatum var. capsulatum infection: 25 years experience of French Guiana. AIDS 2008; 22:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/33\">",
"      Daher EF, Silva GB Jr, Barros FA, et al. Clinical and laboratory features of disseminated histoplasmosis in HIV patients from Brazil. Trop Med Int Health 2007; 12:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/34\">",
"      Antinori S, Magni C, Nebuloni M, et al. Histoplasmosis among human immunodeficiency virus-infected people in Europe: report of 4 cases and review of the literature. Medicine (Baltimore) 2006; 85:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/35\">",
"      Drew RH. Pharmacotherapy of disseminated histoplasmosis in patients with AIDS. Ann Pharmacother 1993; 27:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/36\">",
"      McKinsey DS, Gupta MR, Riddler SA, et al. Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989; 111:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/37\">",
"      Hecht FM, Wheat J, Korzun AH, et al. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1449/abstract/38\">",
"      Goldman M, Zackin R, Fichtenbaum CJ, et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis 2004; 38:1485.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6996 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.25.216.6-8F673A88A0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_26_1449=[""].join("\n");
var outline_f1_26_1449=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antigen detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Direct microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Skin testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antifungal agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Itraconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Fluconazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Moderately severe to severe disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Mild to moderate disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MONITORING OF PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      IMMUNE RECONSTITUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUPPRESSIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PRIMARY PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/6996\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/6996|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/32/24065\" title=\"picture 1A\">",
"      Histoplasmosis spleen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/36/5699\" title=\"picture 1B\">",
"      Histoplasmosis lung granuloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/55/43888\" title=\"picture 1C\">",
"      Histoplasmosis silver stain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/44/31427\" title=\"picture 2\">",
"      Histoplasma from culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/6996|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/36/1613\" title=\"table 1\">",
"      Drug therapy for treatment of histoplasmosis infections in HIV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9321?source=related_link\">",
"      Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21881?source=related_link\">",
"      Diagnosis and treatment of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/63/39924?source=related_link\">",
"      Epidemiology and clinical manifestations of histoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/5/13393?source=related_link\">",
"      Patient information: Histoplasmosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_26_1450="Chronic otitis media, cholesteatoma, and mastoiditis in adults";
var content_f1_26_1450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic otitis media, cholesteatoma, and mastoiditis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/26/1450/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1450/contributors\">",
"     Lawrence R Lustig, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1450/contributors\">",
"     Charles J Limb, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1450/contributors\">",
"     Rachel Baden, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1450/contributors\">",
"     Mary T LaSalvia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/26/1450/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1450/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/26/1450/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/26/1450/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/26/1450/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H26969753\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic otitis media is a recurrent infection of the middle ear",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mastoid air cell tract in the presence of a tympanic membrane perforation. Symptoms commonly associated with chronic ear disease include hearing loss, otorrhea, aural fullness, otalgia, and occasionally true vertigo.",
"   </p>",
"   <p>",
"    Cholesteatoma, a keratinized mass in the middle ear or mastoid, may occur either as a primary lesion or secondary to tympanic membrane perforation. Mastoiditis may occur as a complication of acute or chronic otitis media.",
"   </p>",
"   <p>",
"    Acute otitis media (AOM), an acute illness marked by the presence of middle ear fluid and inflammation of the mucosa that lines the middle ear space, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=see_link\">",
"     \"Acute otitis media in adults (suppurative and serous)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar to acute otitis media, chronic otitis media occurs far more commonly in children. These conditions in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link\">",
"     \"Acute otitis media in children: Diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=see_link\">",
"     \"Acute otitis media in children: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24728?source=see_link&amp;anchor=H12#H12\">",
"     \"Evaluation of otorrhea (ear discharge) in children\", section on 'Chronic suppurative otitis media'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26969760\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of terms are used to categorize chronic infectious or inflammatory conditions of the middle ear, according to the underlying disease process and location.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26969774\">",
"    <span class=\"h2\">",
"     Chronic otitis media",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic otitis media (COM) is defined as an ear with a tympanic membrane perforation in the setting of recurrent or chronic ear infections (",
"    <a class=\"graphic graphic_picture graphicRef64202 \" href=\"UTD.htm?27/15/27888\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign (or inactive) COM is characterized by a dry tympanic membrane perforation, unassociated with active infection.",
"     </li>",
"     <li>",
"      Chronic serous otitis media is characterized by continuous serous drainage (typically straw-colored).",
"     </li>",
"     <li>",
"      Chronic suppurative otitis media (CSOM) is diagnosed when there is persistent purulent drainage through a perforated tympanic membrane.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26969790\">",
"    <span class=\"h2\">",
"     Cholesteatoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholesteatoma refers to a keratinized, desquamated epithelial collection in the middle ear or mastoid and may occur secondary to tympanic membrane perforation, but also may occur as a primary lesion. (See",
"    <a class=\"local\" href=\"#H98017516\">",
"     'Cholesteatoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26969804\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178692471\">",
"    <span class=\"h2\">",
"     Chronic otitis media",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, chronic ear disease often follows episodes of acute otitis media (AOM). Chronic suppurative otitis media (CSOM) is more common in lower socioeconomic areas, possibly related to delay in treatment for AOM, poorer hygienic conditions, increased smoking, or poorer nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/1\">",
"     1",
"    </a>",
"    ]. The point in time when AOM becomes CSOM is controversial, with definitions ranging from two weeks to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CSOM in adults occurs in patients with perforation of the tympanic membrane that will not heal. Typically, there is a history of recurrent ear infections in childhood, with longstanding (months or years) of otorrhea and hearing loss made worse by water exposure.",
"   </p>",
"   <p>",
"    Chronic ear disease occurs as a result of eustachian tube dysfunction, related either to obstruction (usually due to upper respiratory infection or seasonal allergic rhinitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/4,5\">",
"     4,5",
"    </a>",
"    ] or abnormal patency of the eustachian tube. A patulous eustachian tube enables contents of the nasopharynx to reflux into the middle ear space, resulting in chronic inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eustachian tube dysfunction results in chronic negative middle ear pressure exerted on the tympanic membrane, the most compliant boundary of the middle ear. Negative pressure pulls the tympanic membrane medially, and retraction pockets can occur with prolonged exposure, usually within the pars flaccida of the tympanic membrane (",
"    <a class=\"graphic graphic_figure graphicRef57110 \" href=\"UTD.htm?25/31/26099\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This segment of the tympanic membrane accounts for the upper one-sixth of the surface area of the tympanic membrane and lies superior to the anterior and posterior malleolar folds of the tympanic membrane.",
"   </p>",
"   <p>",
"    When a patient has acute otitis media, a serous, mucoid, or purulent effusion builds up behind the tympanic membrane. Tympanic membrane rupture and otorrhea may occur if the positive pressure exerted by this effusion exceeds the tensile strength of the tympanic membrane and eustachian tube dysfunction prevents pressure equilibration. Spontaneous perforations produced under these conditions are part of the compensatory mechanism of the ear and provide a conduit for aeration similar to that produced by myringotomy tubes. In some cases where there are multiple episodes of acute infection, the perforation may become chronic (non-closing). In such instances, the outer epithelial layer of the tympanic membrane grows over the perforation edges, covering the middle fibrous and inner mucosal layers, and prevents the perforation from closing.",
"   </p>",
"   <p>",
"    Perforations of the tympanic membrane are classified as central when the annulus (the ligamentous ring surrounding the tympanic membrane) is preserved and marginal when a portion of the annulus or the entire annulus is involved [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The annulus serves as a protective barrier against squamous epithelial migration into the middle ear. Marginal perforations are more frequently associated with cholesteatoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26969826\">",
"    <span class=\"h2\">",
"     Cholesteatoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term cholesteatoma refers to a keratinized, desquamated epithelial collection in the middle ear or mastoid [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/11\">",
"     11",
"    </a>",
"    ]. The nomenclature of cholesteatoma is misleading, with keratoma perhaps being a better term [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/12\">",
"     12",
"    </a>",
"    ]. Cholesteatomas contain no cholesterol or lipids and are not neoplastic. Cholesteatomas may occur as primary lesions or may be secondary to tympanic membrane perforation or surgery. Congenital cholesteatomas are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42808?source=see_link&amp;anchor=H11#H11\">",
"     \"Cholesteatoma in children\", section on 'Congenital cholesteatomas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary acquired cholesteatomas occur most commonly as a result of eustachian tube dysfunction (",
"    <a class=\"graphic graphic_picture graphicRef76079 \" href=\"UTD.htm?6/8/6272\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Prolonged exposure to negative middle ear pressure causes the tympanic membrane to retract medially. A retraction pocket may eventually become trapped behind the tympanic membrane, inducing inflammatory changes [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/16\">",
"     16",
"    </a>",
"    ]. This epithelial lined pocket accumulates keratinized squamous debris, which forms a cholesteatoma (",
"    <a class=\"graphic graphic_picture graphicRef59937 \" href=\"UTD.htm?20/54/21344\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/11,15\">",
"     11,15",
"    </a>",
"    ]. Poor middle ear ventilation results in delayed resolution of infection, persistence of effusion, and ultimately a retracted or perforated tympanic membrane. With growth and proliferation of squamous epithelium, the cholesteatoma grows in size, often eroding the scutum (the sharp edge of the tympanic ring adjacent to the head of the malleus). Further infection with inflammatory changes can lead to aural polyps and granulation tissue throughout the middle ear and mastoid air cell tracts.",
"   </p>",
"   <p>",
"    Tympanic membrane perforation may lead to a secondary acquired cholesteatoma in a small percentage of cases. Squamous epithelium can migrate through the tympanic membrane defect into the middle ear space, and accumulations of squamous debris result in the cholesteatoma [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. An iatrogenic form of secondary acquired cholesteatoma may develop if squamous epithelium is implanted in the middle ear space during surgery such as tympanoplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cholesteatomas may result in erosion of the ossicles in the middle ear and consequent hearing loss. An earlier theory attributed bony erosion to pressure necrosis from the expanding cholesteatoma itself [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/18\">",
"     18",
"    </a>",
"    ]. Several other mechanisms are now recognized as the cause of bone destruction: enzymatic breakdown of collagen by collagenase, acid phosphatase, and acid protease produced by the cholesteatoma; osteoclastic bone resorption; and pyogenic osteitis [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/19\">",
"     19",
"    </a>",
"    ]. Bacterial overgrowth in the area of the cholesteatoma further contributes to the potential for bone destruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26969833\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In chronic suppurative otitis media (CSOM), typical pathogens reach the middle ear through two routes of spread [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insufflation of respiratory pathogens through the eustachian tube from the nasopharynx into the middle ear",
"     </li>",
"     <li>",
"      Spread from the external ear canal inward through a non-intact tympanic membrane",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies of CSOM differ in regard to patient age, geography, and the presence of complications such as cholesteatoma, and these inconsistencies likely impact some of the variation in reported pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Differences in sampling and processing techniques may also account for some of the variability observed in microbiologic diagnoses. Studies reported in the literature most often sample aural discharge through a sterilized otoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. Swabs of the external ear canal are not adequate for sampling, as they are often contaminated by ear canal flora and provide misleading information [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/21,27\">",
"     21,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aerobes, anaerobes, and fungi are all potential pathogens in CSOM. Knowledge of the true frequency of polymicrobial infection, particularly the extent of anaerobe involvement, is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pseudomonas aeruginosa and Staphylococcus aureus are the most commonly isolated aerobic bacteria in several large case series [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/20,22-25,30\">",
"       20,22-25,30",
"      </a>",
"      ]. The ability of these organisms to form biofilm may contribute to their frequency in CSOM [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/2\">",
"       2",
"      </a>",
"      ]. The prevalence of methicillin-resistant S aureus (MRSA) varies by region and importantly also predicts differences in susceptibility to commonly-used topical therapies (quinolones and aminoglycosides) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. Antibiotic susceptibility to Pseudomonas can vary widely, making it important to perform susceptibility testing to guide therapy when Pseudomonas infection is suspected or patients fail to respond to an initial empiric course of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Less-frequently isolated organisms include enteric gram-negative rods such as Klebsiella, Proteus, and E. coli [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/20,22,23,31\">",
"       20,22,23,31",
"      </a>",
"      ]. Enteric gram-negative rods may be more common in areas at higher risk of infection due to poor hygiene conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The role of anaerobes in CSOM has been variably reported, with frequencies of anaerobic isolates ranging from 8 to 59 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/29\">",
"       29",
"      </a>",
"      ]. The lack of standardized technique for sample collection and culture protocol likely accounts for demonstrated large part of the wide range of incidence.",
"     </li>",
"     <li>",
"      Fungi, particularly Aspergillus sp. and Candida sp., although rare, are reported as pathogens as well [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/22,24\">",
"       22,24",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The expected antimicrobial resistance profile in CSOM will vary based on several factors including geography, prior healthcare contact, and previous receipt of antibiotics. Cultures for definitive microbiologic diagnosis and susceptibility testing should be pursued if resistant organisms are suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/21,27\">",
"     21,27",
"    </a>",
"    ]. Cultures should be obtained by microscopy and aspiration; swabs of the ear canal are more likely to be contaminated. ENT referral for otoscopy is often indicated as it is necessary to remove any obstructing wax, debris, or drainage to visualize the ear drum and middle ear if a perforation is present.",
"   </p>",
"   <p>",
"    Cholesteatoma can be associated with a polymicrobial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/26\">",
"     26",
"    </a>",
"    ], however, the most commonly isolated pathogens remain S. aureus and P. aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/23,24,26\">",
"     23,24,26",
"    </a>",
"    ]. The development of eroded ossicles may be more common with Proteus sp. and failure to control infection is more common when Pseudomonas sp. is isolated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25111276\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98017535\">",
"    <span class=\"h2\">",
"     Chronic suppurative otitis media",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) defines chronic suppurative otitis media (CSOM) as &ldquo;a chronic inflammation of the middle ear and mastoid cavity, which presents with recurrent ear discharges or otorrhea through a tympanic perforation&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/1\">",
"     1",
"    </a>",
"    ]. The WHO definition requires that otorrhea be present for only two weeks, but the focus of WHO is primarily on worldwide disease prevention in children. Practically, most otolaryngologists consider the diagnosis of CSOM to be established when discharge persists, despite treatment, for periods varying from six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/2\">",
"     2",
"    </a>",
"    ] to up to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common symptom of CSOM is the presence of recurrent or persistent purulent ear drainage. CSOM is most often painless and patients usually present without fever or other systemic signs of infection. The drainage may be foul smelling. &nbsp;",
"   </p>",
"   <p>",
"    Patients may also report hearing loss. The degree of hearing loss is related to the location and size of the tympanic membrane perforation, the status of the ossicles, as well as to the duration of chronic damage [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physical examination is notable for otorrhea in the presence of a perforated tympanic membrane.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98017516\">",
"    <span class=\"h2\">",
"     Cholesteatoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical presenting features of cholesteatoma may vary. Some patients may be totally asymptomatic. Others may present with some combination of hearing loss, dizziness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    otorrhea. Cholesteatomas associated with tympanic membrane perforation are typically detected earlier than primary acquired cholesteatomas as the inferior portion of the ear drum is easier to inspect, and hearing loss occurs early [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hearing loss occurs late in the course of primary cholesteatomas since the pars flaccida is the non-vibratory portion of the tympanic membrane. Late conductive hearing loss is also due to erosion of the ossicles, typically the distal portion of the incus. Hearing loss can occur earlier when cholesteatomas are associated with tympanic membrane perforation (eg, secondary cholesteatomas) due to involvement of the vibratory surface area of the tympanic membrane (pars tensa).",
"   </p>",
"   <p>",
"    The otoscopic findings in cholesteatoma depend on the type of cholesteatoma (primary or secondary).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20907628\">",
"    <span class=\"h3\">",
"     Primary cholesteatoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary acquired cholesteatomas are typically found in the posterosuperior quadrant of the tympanic membrane, in the pars flaccida (",
"    <a class=\"graphic graphic_picture graphicRef76079 \" href=\"UTD.htm?6/8/6272\">",
"     picture 2",
"    </a>",
"    ). The surface of the cholesteatoma is often obscured by crusting or desquamated debris on its lateral surface. Retractions of the pars flaccida lead to attic cholesteatomas that can be particularly difficult to visualize.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20907635\">",
"    <span class=\"h3\">",
"     Secondary cholesteatoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a cholesteatoma is associated with a perforation (secondary acquired cholesteatoma), a pearly mass is usually evident behind the tympanic membrane. These cholesteatomas may appear as skin that has replaced the mucosa of the middle ear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178692374\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful ear examination can establish the diagnosis, with attention aimed to determine if there is a cholesteatoma. This may require otomicroscopy with suctioning, necessitating referral to an otolaryngologist. For routine serous otitis media, the drum is typically intact with a yellowish hue, or there may be visible air bubbles behind the tympanic membrane. In cases of chronic suppurative otitis media (CSOM), there is typically a perforation that may be partial or complete, often with associated purulent otorrhea and inflamed middle ear mucosa. In the case of a primary cholesteatoma, the otoscopic examination will reveal a retracted area of the tympanic membrane, usually of the pars flaccida, but also occasionally of the pars tensa, that contains squamous debris or inflammatory tissue. Alternatively, there may be an obstructive polyp. In secondary cholesteatomas, the tympanic membrane may be completely intact (after a perforation has healed, for example) but a white mass may be visible behind the tympanic membrane.",
"   </p>",
"   <p>",
"    Gram stains and cultures, to assist in guiding therapy, are usually reserved for cases that fail standard topical therapy. Specimens for culture should be acquired through aspiration using a sterile otomicroscope, as specimens obtained by direct ear swabs are typically contaminated with flora from the outer ear canal.",
"   </p>",
"   <p>",
"    If there is no response to medical therapy, persistent granulation tissue should be biopsied to rule out a neoplastic or granulomatous process [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/35\">",
"     35",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Hearing loss is often reported, and formal audiometry should be considered in all patients who report hearing loss or present with ongoing otorrhea to establish the type and degree of hearing loss.",
"   </p>",
"   <p>",
"    Accurate diagnosis of primary cholesteatoma mandates a careful cleaning of the canal and drum in order to fully inspect for retractions under microscopy. While standard otoscopy may be sufficient, cholesteatoma is better visualized with otomicroscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178692851\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging, typically with a computed tomography (CT) scan, should be performed if extracranial complications are suspected. These patients are often systemically ill and will have localizing signs of infection. Magnetic resonance imaging (MRI) is more sensitive and should be ordered when intracranial complications are suspected.",
"   </p>",
"   <p>",
"    The diagnosis of cholesteatoma in chronic ear disease is occasionally supplemented by CT scanning of the temporal bones. These images can help to define the extent of the cholesteatoma. A CT may help to define areas of erosion or point to an area of potential fistula formation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/4,36,37\">",
"     4,36,37",
"    </a>",
"    ]. MRI provides excellent soft tissue detail but lacks the bony detail needed for operative planning and thus is complementary to CT. MRI can also be useful for following possible recurrence of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178692479\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for chronic suppurative otitis media (CSOM) includes external otitis, granulomatous disease (eg, granulomatosis with polyangiitis [Wegener&rsquo;s], histiocytosis X), mycobacterial infection, and malignancy such as nasopharyngeal carcinoma. The presence of pain or failure to respond to medical therapy should lead to further exploration to establish a definitive diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link\">",
"     \"External otitis: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link&amp;anchor=H452648804#H452648804\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=see_link\">",
"     \"Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178692489\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178692617\">",
"    <span class=\"h2\">",
"     Mastoiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A spectrum of disease is associated with mastoiditis. Mastoid effusion is often seen on CT scan in patients with both acute otitis media (AOM) and chronic suppurative otitis media (CSOM) and is not usually clinically significant. Symptomatic coalescent mastoiditis is a rare complication of both acute and chronic otitis media, but can be serious due to proximity of the mastoid to the posterior cranial fossa, lateral sinuses, facial nerve canal, semicircular canals, and the petrous tip of the temporal bone. Mastoiditis complicating CSOM can result in bony erosion and temporal lobe abscess or can cause septic thrombosis of the lateral sinus.",
"   </p>",
"   <p>",
"    Acute mastoiditis occurs more commonly in children than adults, and its incidence has declined dramatically in the antibiotic era with routine use of antibiotics for treatment of otitis media. It is a rare occurrence in adults, but can complicate CSOM with or without cholesteatoma. One study that reviewed almost 3000 cases of CSOM in a nine-year period in Turkey reported 25 cases of mastoid abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical mastoiditis may present with fever, posterior ear pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    local erythema over the mastoid bone, edema of the pinna, or a posteriorly and downward displaced auricle. In coalescent mastoiditis, CT demonstrates characteristic loss of the trabecular bone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT scan should always be performed when mastoiditis is suspected. If there is a concern for an intracranial process (ie, sigmoid sinus thrombosis, intracranial abscess), then an MRI scan should also be considered. Patients with acute mastoiditis should be admitted to the hospital and IV antibiotics should be started.",
"   </p>",
"   <p>",
"    Antibiotics for the treatment of mastoiditis presenting as a complication of chronic otitis should include coverage for Staphylococcus aureus, Pseudomonas, and enteric gram-negative rods, as well as Streptococcus pneumoniae and Haemophilus influenza. If patients do not respond to conservative therapy with IV antibiotics, further intervention is warranted. This involves mastoidectomy for debridement of necrotic bone. Myringotomy is an adjunct to mastoidectomy for the treatment of acute mastoiditis. When cholesteatoma is present, a tympanomastoidectomy is performed to remove both the necrotic bone in the mastoid and cholesteatoma. (See",
"    <a class=\"local\" href=\"#H26969910\">",
"     'Surgical treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178692644\">",
"    <span class=\"h2\">",
"     Facial nerve palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSOM with or without cholesteatoma can be complicated by facial nerve palsy. This can occur through involvement of the dehiscent nerve or through direct bony erosion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The onset is usually gradual. In one case series of 70 patients with complicated CSOM, 14 percent of the patients had accompanying facial palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/42\">",
"     42",
"    </a>",
"    ]. Treatment of facial paralysis in the setting of CSOM, with or without cholesteatoma, requires surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/40\">",
"     40",
"    </a>",
"    ].",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H178692651\">",
"    <span class=\"h2\">",
"     Intracranial complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial complications of CSOM are potentially life-threatening and require immediate intervention. They include suppurative thrombophlebitis of the lateral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cavernous sinuses, meningitis, and intracranial abscesses [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/39\">",
"     39",
"    </a>",
"    ]. These complications are rare in the era of effective antibiotics, with one large review estimating an overall rate of 0.1 to 2.0 percent. In a retrospective chart review involving 33 patients over a 15-year period in Brazil, meningitis and intracranial abscess were the most common serious problems [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Signs of intracranial involvement are severe earache, seizures, fever, constant and persistent headache, nausea and vomiting, or focal neurological symptoms. Patients who present with these complications should be evaluated and treated promptly. Empiric intravenous therapy should be started to cover the typical pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas. (See",
"    <a class=\"local\" href=\"#H14108077\">",
"     'Systemic antibiotics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26969894\">",
"    <span class=\"h1\">",
"     MEDICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of the treatment of chronic suppurative otitis media (CSOM) are to stop otorrhea, heal the tympanic membrane, eradicate current infection, prevent complications, and prevent recurrence. The optimal treatment strategy remains to be determined but involves a combination of adherence to the principles of aural hygiene and the appropriate utilization of antibiotic therapy and surgical intervention involving the tympanic membrane, middle ear, and mastoid. Intranasal glucocorticoids, decongestants, and antihistamines are not indicated in the treatment of CSOM. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20907773\">",
"    <span class=\"h2\">",
"     Aural toilet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no randomized controlled trials evaluating its use, most experts agree that aural irrigation is a key component of treating CSOM [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/21,27,44\">",
"     21,27,44",
"    </a>",
"    ]. Aural toilet should be used as a supplement to antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/21,44\">",
"     21,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The process of aural irrigation serves the dual purpose of cleaning the ear of mucoid discharge, temporarily reducing the quantity of infected material from the middle ear, and facilitating middle ear penetration of topical antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/21,27,45\">",
"     21,27,45",
"    </a>",
"    ]. While an otolaryngologist often performs the initial procedure with the use of microscopy and suction, aural cleansing also can be performed by the patient.",
"   </p>",
"   <p>",
"    A variety of irrigation solutions may be used, including 1:1 dilutions of vinegar, saline, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"     povidone iodine",
"    </a>",
"    with water, though some of these solutions can occasionally cause discomfort when used (ie, vinegar). Solutions should be warmed to near body temperature to prevent vertigo. They can be instilled into the ear with a rubber bulb or a dropper and removed by suctioning using the same instrument, or the ear can be mopped dry after fluid instillation. Aural irrigation is typically performed two to three times daily until discharge disappears [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20908957\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14108070\">",
"    <span class=\"h3\">",
"     Topical antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical antibiotics are the first-line treatment for uncomplicated otorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/21,27,46,47\">",
"     21,27,46,47",
"    </a>",
"    ]. Topical therapy may be more effective than systemic medications in resolving otorrhea due to the difficulty of systemic drug penetration through the devascularized mucosa of the middle ear and mastoid. Additionally, initial use of topical therapy may be preferable to systemic antibiotics because increased concentration of topical agents in the middle ear may decrease the rate of resistance as well as limit systemic absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/21,27,48,49\">",
"     21,27,48,49",
"    </a>",
"    ]. However, there are reports of increasing quinolone resistance in CSOM with the use of topical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the literature for medical therapy for CSOM is not robust, there is reasonable evidence for the efficacy of topical fluoroquinolones. Due to their good safety profile, topical fluoroquinolones are preferred to alternative agents [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/27,46,50-54\">",
"     27,46,50-54",
"    </a>",
"    ] and are the only ototopical agents approved in the United States for use in an ear with a tympanic membrane perforation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of nine randomized trials (833 participants) found that trials were generally of poor methodologic quality with short follow-up but that topical quinolone antibiotics were better than systemic antibiotics at clearing discharge at two weeks (RR 3.21, 95% CI 1.88-5.49) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/46\">",
"       46",
"      </a>",
"      ]. The evidence was not clear comparing other topical antibiotics with systemic antibiotics.",
"     </li>",
"     <li>",
"      In a systematic review of five randomized trials, there was not statistical difference found between quinolone and non-quinolone antibiotics; a positive trend toward quinolones was not seen after accounting for trial heterogeneity [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial of 155 adults with CSOM treated with topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (0.2 percent) compared to 138 patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"       polymyxin B",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"       neomycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      therapy, there was no significant difference in the rate of absence of otorrhea or culture negative drainage at 6 to 12 days [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several studies suggest that fluoroquinolone drops may be superior to topical aminoglycoside agents, but data are limited by small sample sizes [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/20,46,53,57,58\">",
"       20,46,53,57,58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Topical quinolone antibiotics were significantly better than topical antiseptics at one to four weeks in seven randomized trials, while results were more mixed when comparing nonquinolone topical drops with antiseptics [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      No benefit was seen for the addition of systemic antibiotics to topical therapy in a review of three randomized trials [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The standard quinolone therapy consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    drops used twice daily for a two-week course, although up to four weeks may provide benefit in some cases without increasing complication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/53,56,59\">",
"     53,56,59",
"    </a>",
"    ]. Many sources recommend warming the otic solutions in the hands for a few minutes, as instillation of cold drops may cause dizziness. Patient should lie on",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    side with the affected ear up during and after instillation. Some sources recommend pushing on the tragus several times to facilitate movement of the drops into the middle ear.",
"   </p>",
"   <p>",
"    Due to the concern for ototoxicity with aminoglycoside containing agents, the 2004 American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) consensus panel recommended that &ldquo;When possible, topical antibiotic preparations free of potential ototoxicity are preferred over ototopical agents that have the potential for injury if the middle ear and mastoid are open&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a lack of evidence to evaluate the benefit of the addition of a topical corticosteroid to topical antibiotic therapy, but the AAO-HNS consensus panel supported its consideration if granulation tissue is present [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14108077\">",
"    <span class=\"h3\">",
"     Systemic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic antibiotics should be considered in patients at risk for complicated or invasive ear infections or in those who have received several courses of empiric topical therapy and are at higher risk for resistant organisms. In these circumstances, cultures should be obtained for microbiologic diagnosis and susceptibility data to guide selection of antimicrobial agents [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/21,25,27,30,46\">",
"     21,25,27,30,46",
"    </a>",
"    ]. Empiric treatment while waiting for culture data should be based on the individual&rsquo;s previous cultures and prior antibiotic exposure, as well as local antibiotic resistance profiles.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Previous antibiotic exposure is a concern for potential failure of topical therapy with quinolones due to bacterial resistance to this class of drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/30\">",
"       30",
"      </a>",
"      ]. In one study of 231 outpatients, 88 had otorrhea that failed to resolve after two to three weeks of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      drops. Ciprofloxacin resistant Pseudomonas aeruginosa was isolated in all 88 patients. In this study, imipenem was the antimicrobial agent with the most reliable sensitivity [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CSOM secondary to S. aureus should also be guided by culture data with empiric therapy based on systemic symptoms and risk factors for antibiotic resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26969910\">",
"    <span class=\"h1\">",
"     SURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is indicated for patients who develop complications of chronic otitis, to remove infected tissue in the middle ear or mastoid, and to repair ear damage that results in hearing loss. Surgical therapy is guided by the following principles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eradication of irreversible disease &mdash; Abnormal squamous epithelium (cholesteatoma), polypoid disease, and infected bone must be removed in order to create a dry, safe ear that is free of infection [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Preservation of anatomic contour &mdash; It is important to preserve the acoustic characteristics of the ear, when possible, though some patients with intractable disease will require a more aggressive approach that may impact conductive hearing. (See",
"      <a class=\"local\" href=\"#H26969931\">",
"       'Mastoidectomy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Reconstruction of the sound transformer mechanism &mdash; Ossicular prostheses are available for reconstruction. The presence of healthy, non-diseased mucosa is critically important to achieve success [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/11,60\">",
"       11,60",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H26969938\">",
"       'Ossicular chain reconstruction'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Restoration of tympanic and mastoid aeration &mdash; Aeration is required for both maintenance of a disease-free state and for maximal auditory function [",
"      <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/61,62\">",
"       61,62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term monitoring is essential to rule out recurrent disease in the middle ear or mastoid, and to maximize cavity hygiene [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26969917\">",
"    <span class=\"h2\">",
"     Cholesteatoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholesteatoma removal is typically performed in conjunction with tympanoplasty and, if the lesion extends superiorly or posteriorly, mastoidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/64\">",
"     64",
"    </a>",
"    ]. While concurrent treatment of allergic disease, chronic sinusitis, and adenotonsillar hypertrophy is helpful in conjunction with cholesteatoma removal, none of these measures will prevent the need for eventual surgical excision.",
"   </p>",
"   <p>",
"    Surgical approaches to cholesteatoma are determined by three principal considerations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The extent of the disease",
"     </li>",
"     <li>",
"      The size and pattern of mastoid pneumatization",
"     </li>",
"     <li>",
"      Eustachian tube dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The surgical techniques that are employed for cholesteatoma are classified as tympanoplasty with or without mastoidectomy, and with or without ossicular reconstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26969931\">",
"    <span class=\"h2\">",
"     Mastoidectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mastoidectomy is a crucial component of surgical treatment when cholesteatoma extends beyond the middle ear space, when mastoid cells become chronically infected with buildup of granulation tissue that prevents proper aeration of the mastoid, or when there is a subperiosteal abscess over the surface of the mastoid cortex.",
"   </p>",
"   <p>",
"    Mastoidectomy involves the removal of the mastoid air cells, with preservation of the tegmen tympani, sigmoid sinus, facial nerve, vestibular labyrinth, and ossicles. The goal of surgery is eradication of disease and improved aeration of the mastoid-middle ear system.",
"   </p>",
"   <p>",
"    Intact canal wall versus canal wall down approaches differ in the exposure they offer, technical difficulty, prospects for post-operative hearing, and needs for postoperative care. In canal wall intact mastoidectomy, the air cells of the mastoid are removed while the posterior bony external auditory canal wall is kept intact. Intact canal wall procedures provide greater convenience of postoperative care and often promote a better level of conductive hearing. Maintaining the bony canal obviates the need to take precautions against exposure to water and typically provides a better fit for a hearing aid if one is needed postoperatively. However, canal wall intact mastoidectomy procedures are technically more challenging and have a higher rate of recurrent cholesteatoma than do canal wall down procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In many cases, the extent of disease or the need for greater exposure in cholesteatoma removal mandates removal of the posterior bony external auditory canal (canal wall down mastoidectomy). This exteriorizes the entire mastoid cavity, promoting maximal mastoid aeration and allowing long-term monitoring for recurrence of cholesteatoma. Open cavity techniques typically lead to a decrease in hearing [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/66\">",
"     66",
"    </a>",
"    ]. There is a risk of recurrent discharge from bacterial or fungal overgrowth on retained debris within the open cavity. This underscores the need for post-operative vigilance over years and maintenance of a clean, safe cavity with regular cleaning by an otolaryngologist (",
"    <a class=\"graphic graphic_picture graphicRef52515 \" href=\"UTD.htm?14/31/14836\">",
"     picture 4",
"    </a>",
"    ). It is crucial that a wide meatoplasty be performed to enable inspection of the complete extent of the mastoid cavity. &nbsp;",
"   </p>",
"   <p>",
"    No controlled prospective studies are available that compare intact canal versus canal wall down procedures. Outcomes reported from case series comparing the two techniques likely involve selection bias, as intact canal wall mastoidectomies tend to be reserved for more limited disease while more aggressive cholesteatomas will often be treated with canal wall down mastoidectomies.",
"   </p>",
"   <p>",
"    Recurrent cholesteatomas are more common in intact canal wall procedures due to the formation of retraction pockets in the grafted drum into the middle ear, epitympanum, or facial recess [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/63,65\">",
"     63,65",
"    </a>",
"    ]. An intact canal wall procedure for cholesteatoma usually requires re-exploration within one year to rule out residual or recurrent disease; residual or recurrent cholesteatoma is found in re-exploration of canal wall intact procedures in approximately one-third of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/63,65\">",
"     63,65",
"    </a>",
"    ]. Re-exploration enables the detection of lesions that are typically less than 5 mm in greatest diameter and enables complete removal with minimal dissection. Multiple recurrences of cholesteatomas are not uncommon. In some cases, a very active recurrent cholesteatoma found during the second stage procedure may warrant a more radical procedure in which the canal wall is removed.",
"   </p>",
"   <p>",
"    Mastoid cavities are occasionally obliterated using homograft or allograft materials. Advantages of obliteration include less cold sensitivity, improved hearing, and decreased drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/67\">",
"     67",
"    </a>",
"    ]. However, such reconstructions may be susceptible to recurrent infection either due to primary infection of the graft material, or blockage of adjacent air cell tracts, and recurrent disease if the primary cholesteatoma matrix was not completely eradicated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14109348\">",
"    <span class=\"h2\">",
"     Tympanoplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;In common practice, tympanoplasty refers to reconstructive surgery of the ear drum and ossicular chain. More formally, tympanoplasty is a procedure to eradicate disease in the middle ear and reconstruct the ossicular chair, which may or may not involve tympanic membrane grafting or mastoid surgery.",
"   </p>",
"   <p>",
"    Tympanoplasty is generally performed after infection has been eradicated for a minimum of three months.",
"   </p>",
"   <p>",
"    Tympanoplasty is typically carried out through either an endaural incision for smaller cholesteatomas or a postauricular incision for larger ones [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/69\">",
"     69",
"    </a>",
"    ]. Care is taken with either approach to isolate and preserve the tympanic branch of the postauricular artery, a branch of the occipital artery of the external carotid system [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two main types of tympanoplasty are medial graft and lateral graft tympanoplasty. The medial graft technique is useful for most central perforations. Although a more surgically demanding procedure, the lateral graft technique affords better visualization of the anterior tympanic membrane and is useful for difficult marginal or large perforations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26969938\">",
"    <span class=\"h2\">",
"     Ossicular chain reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholesteatoma and chronic otitis media have the propensity to erode bone. In many cases, the small ossicular chain bones (malleus, incus, and stapes) are either partially or totally destroyed secondary to cholesteatoma and chronic infection. The long process of the incus, due to its relatively scant vascular supply, appears especially vulnerable to bony destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When chronic ear disease results in significant hearing loss due to ossicular involvement, an important component of surgical therapy is reconstruction of the ossicular chain. Ossicular chain reconstruction employs a partial or total prosthesis to provide a medium for sound conduction where ossicular discontinuity is present.",
"   </p>",
"   <p>",
"    Hearing rehabilitation surgery is frequently performed as part of a second-stage procedure after tympanomastoidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. With improvements in prosthesis material selection and design, combined with a better understanding of indications for ossicular reconstruction, hearing rehabilitation is often successfully achieved in the treatment of chronic ear disorders. Closure of the air-bone gap to within 20 dB has been reported in 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/26/1450/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14110098\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic otitis media is a recurrent infection of the middle ear",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mastoid air cell tract in the presence of a tympanic membrane perforation. Chronic suppurative otitis media (CSOM) is diagnosed when there is persistent purulent drainage through a perforated tympanic membrane. Cholesteatoma refers to a keratinized, desquamated epithelial collection in the middle ear or mastoid and may occur secondary to tympanic membrane perforation, but also may occur as a primary lesion. (See",
"      <a class=\"local\" href=\"#H26969760\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic ear disease occurs as a result of eustachian tube dysfunction with negative middle ear pressure causing rupture of the tympanic membrane. Cholesteatomas may occur as primary lesions, or may be secondary to tympanic membrane perforation or surgery. Cholesteatomas may result in erosion of the ossicles in the inner ear and consequent hearing loss. (See",
"      <a class=\"local\" href=\"#H26969804\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pseudomonas aeruginosa and Staphylococcus aureus are the most commonly isolated aerobic bacteria in several large case series of chronic suppurative otitis media. The prevalence of methicillin-resistant S aureus (MRSA) varies by region. Less frequently, gram-negative rods or anaerobes are found and fungi are occasionally reported. Cholesteatoma can be associated with a polymicrobial infection, but the most commonly isolated pathogens remain S. aureus and P. aeruginosa. (See",
"      <a class=\"local\" href=\"#H26969833\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although definitions vary, most otolaryngologists consider the diagnosis of chronic suppurative otitis media when discharge persists through a tympanic membrane perforation for six weeks to three months. CSOM is often painless, though hearing loss if often reported. Cholesteatomas are often asymptomatic, or may be associated with hearing loss, dizziness,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      otorrhea. The presence of cholesteatoma should always be investigated in patients with CSOM and usually requires otomicroscopy. (See",
"      <a class=\"local\" href=\"#H25111276\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CSOM can often be made with direct otoscopy, but referral to an otolaryngologist for otomicroscopy with suctioning is indicated if the diagnosis is unclear or inadequate visualization precludes the ability to rule out a cholesteatoma. Cultures obtained by direct ear swabbing are not helpful due to contamination. Imaging with CT is indicated if extracranial complications are suspected (patients with systemic illness); MRI is indicated if an intracranial complication is suspected and may be an adjunct to CT for evaluation of cholesteatoma for operative planning. (See",
"      <a class=\"local\" href=\"#H178692374\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While a mastoid effusion and inflammation is commonly seen by CT in patients with acute or chronic otitis media, symptomatic mastoiditis is a rare and potentially serious complication. Clinical mastoiditis may present with fever, ear pain, edema, and a displaced auricle. Treatment includes aggressive antibiotics to include coverage for S aureus and enteric gram-negative rods when associated with chronic otitis. Surgery is required if abscess is present. (See",
"      <a class=\"local\" href=\"#H178692617\">",
"       'Mastoiditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of CSOM include facial nerve palsy, suppurative thrombophlebitis of the lateral or cavernous sinuses, meningitis, and intracranial abscesses. (See",
"      <a class=\"local\" href=\"#H178692489\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aural toilet is an important component of treatment for CSOM, involving ear irrigation two to three times daily. We recommend initial treatment for chronic suppurative otitis media with a topical quinolone antibiotic (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Due to the potential for ototoxicity in the presence of a ruptured tympanic membrane, we suggest not using topical aminoglycosides when alternative agents are available (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We recommend not using systemic antibiotics as an adjunct to topical drops for initial treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). However, systemic antibiotics are indicated for patients with complications of CSOM, for those who fail to respond to topical therapy after two to three weeks, and for those who have been previously treated with several courses of empiric topical therapy and are at risk for resistant organisms. Cultures should be obtained prior to initiating systemic antibiotics. (See",
"      <a class=\"local\" href=\"#H26969894\">",
"       'Medical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery is indicated for patients who develop complications of chronic otitis, to remove infected tissue in the middle ear or mastoid, and to repair ear damage that results in hearing loss. Surgery is also indicated for management of cholesteatoma, as spontaneous resolution is not expected. Surgery may include mastoidectomy, tympanoplasty,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ossicular reconstruction. (See",
"      <a class=\"local\" href=\"#H26969910\">",
"       'Surgical treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Chronic suppurative otitis media: Burden of illness and management options. World Health Organization, Geneva, Switzerland, 2004. file://www.who.int/pbd/deafness/activities/hearing_care/otitis_media.pdf (Accessed on January 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/2\">",
"      Roland PS. Chronic suppurative otitis media: a clinical overview. Ear Nose Throat J 2002; 81:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/3\">",
"      Goycoolea MV, Hueb MM, Ruah C. Otitis media: the pathogenesis approach. Definitions and terminology. Otolaryngol Clin North Am 1991; 24:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/4\">",
"      Jung TT, Hanson JB. Classification of otitis media and surgical principles. Otolaryngol Clin North Am 1999; 32:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/5\">",
"      Seibert JW, Danner CJ. Eustachian tube function and the middle ear. Otolaryngol Clin North Am 2006; 39:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/6\">",
"      Poe DS. Diagnosis and management of the patulous eustachian tube. Otol Neurotol 2007; 28:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/7\">",
"      Danner CJ. Middle ear atelectasis: what causes it and how is it corrected? Otolaryngol Clin North Am 2006; 39:1211.",
"     </a>",
"    </li>",
"    <li>",
"     Wiet RJ, Micco A, Bedoya O. Cholesteatoma. In: Therapy in Otolaryngology-Head &amp; Neck Surgery, Gates GA (Ed), Mosby, Baltimore 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/9\">",
"      da Costa SS, Alves de Souza LC, Ribeiro de Toledo Piza M. The flexible endaural tympanoplasty: pathology-guided, pathogenesis-oriented surgery for the middle ear. Otolaryngol Clin North Am 1999; 32:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/10\">",
"      Oktay MF, Cureoglu S, Schachern PA, et al. Tympanic membrane changes in central tympanic membrane perforations. Am J Otolaryngol 2005; 26:393.",
"     </a>",
"    </li>",
"    <li>",
"     Glasscock M, Haynes D, Storper I, Bohrer P. Surgery for chronic ear disease. In: Clinical Otology, Hughes G, Pensak M (Eds), Thieme, New York 1997. p.215.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/12\">",
"      Wullstein HL, Wullstein SR. Cholesteatoma. Etiology, nosology and tympanoplasty. ORL J Otorhinolaryngol Relat Spec 1980; 42:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/13\">",
"      Persaud R, Hajioff D, Trinidade A, et al. Evidence-based review of aetiopathogenic theories of congenital and acquired cholesteatoma. J Laryngol Otol 2007; 121:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/14\">",
"      Semaan MT, Megerian CA. The pathophysiology of cholesteatoma. Otolaryngol Clin North Am 2006; 39:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/15\">",
"      Ramakrishnan Y, Kotecha A, Bowdler DA. A review of retraction pockets: past, present and future management. J Laryngol Otol 2007; 121:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/16\">",
"      Sudhoff H, Tos M. Pathogenesis of sinus cholesteatoma. Eur Arch Otorhinolaryngol 2007; 264:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/17\">",
"      Vikram BK, Udayashankar SG, Naseeruddin K, et al. Complications in primary and secondary acquired cholesteatoma: a prospective comparative study of 62 ears. Am J Otolaryngol 2008; 29:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/18\">",
"      WALSH TE, COVELL WP, OGURA JH. The effect of cholesteatosis on bone. Ann Otol Rhinol Laryngol 1951; 60:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/19\">",
"      Chole RA, Donald PJ. Petrous apicitis. Clinical considerations. Ann Otol Rhinol Laryngol 1983; 92:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/20\">",
"      Verhoeff M, van der Veen EL, Rovers MM, et al. Chronic suppurative otitis media: a review. Int J Pediatr Otorhinolaryngol 2006; 70:1.",
"     </a>",
"    </li>",
"    <li>",
"     Acuin, J. Chronic Suppurative otitis media. Burden of Illness and Management Options. World Health Organization. Geneva, Switzerland, 2004. who.int/pbd/deafness/activities/hearing_care/otitis_media.pdf (Accessed on January 05, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/22\">",
"      Yeo SG, Park DC, Hong SM, et al. Bacteriology of chronic suppurative otitis media--a multicenter study. Acta Otolaryngol 2007; 127:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/23\">",
"      Vartiainen E, Vartiainen J. Effect of aerobic bacteriology on the clinical presentation and treatment results of chronic suppurative otitis media. J Laryngol Otol 1996; 110:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/24\">",
"      Park DC, Lee SK, Cha CI, et al. Antimicrobial resistance of Staphylococcus from otorrhea in chronic suppurative otitis media and comparison with results of all isolated Staphylococci. Eur J Clin Microbiol Infect Dis 2008; 27:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/25\">",
"      MacNeil SD, Westerberg BD, Romney MG. Toward the development of evidence-based guidelines for the management of methicillin-resistant Staphylococcus aureus otitis. J Otolaryngol Head Neck Surg 2009; 38:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/26\">",
"      Ricciardiello F, Cavaliere M, Mesolella M, Iengo M. Notes on the microbiology of cholesteatoma: clinical findings and treatment. Acta Otorhinolaryngol Ital 2009; 29:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/27\">",
"      Hannley MT, Denneny JC 3rd, Holzer SS. Use of ototopical antibiotics in treating 3 common ear diseases. Otolaryngol Head Neck Surg 2000; 122:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/28\">",
"      Brook I, Burke P. The management of acute, serous and chronic otitis media: the role of anaerobic bacteria. J Hosp Infect 1992; 22 Suppl A:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/29\">",
"      Brook I. The role of anaerobic bacteria in otitis media: microbiology, pathogenesis, and implications on therapy. Am J Otolaryngol 1987; 8:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/30\">",
"      Jang CH, Park SY. Emergence of ciprofloxacin-resistant pseudomonas in chronic suppurative otitis media. Clin Otolaryngol Allied Sci 2004; 29:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/31\">",
"      Lee SK, Lee MS, Jung SY, et al. Antimicrobial resistance of Pseudomonas aeruginosa from otorrhea of chronic suppurative otitis media patients. Otolaryngol Head Neck Surg 2010; 143:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/32\">",
"      van Hasselt P, van Kregten E. Treatment of chronic suppurative otitis media with ofloxacin in hydroxypropyl methylcellulose ear drops: a clinical/bacteriological study in a rural area of Malawi. Int J Pediatr Otorhinolaryngol 2002; 63:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/33\">",
"      Maharjan M, Kafle P, Bista M, et al. Observation of hearing loss in patients with chronic suppurative otitis media tubotympanic type. Kathmandu Univ Med J (KUMJ) 2009; 7:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/34\">",
"      Holt JJ. Cholesteatoma and otosclerosis: two slowly progressive causes of hearing loss treatable through corrective surgery. Clin Med Res 2003; 1:151.",
"     </a>",
"    </li>",
"    <li>",
"     Lee, K. Essential Otolaryngology, 8, McGraw-Hil, New York, NY 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/36\">",
"      Roland PS, Meyerhoff WL. Open-cavity tympanomastoidectomy. Otolaryngol Clin North Am 1999; 32:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/37\">",
"      Swartz JD. Imaging diagnosis of middle ear lesions. Curr Probl Diagn Radiol 2002; 31:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/38\">",
"      Dubrulle F, Souillard R, Chechin D, et al. Diffusion-weighted MR imaging sequence in the detection of postoperative recurrent cholesteatoma. Radiology 2006; 238:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/39\">",
"      Osma U, Cureoglu S, Hosoglu S. The complications of chronic otitis media: report of 93 cases. J Laryngol Otol 2000; 114:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/40\">",
"      Smith JA, Danner CJ. Complications of chronic otitis media and cholesteatoma. Otolaryngol Clin North Am 2006; 39:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/41\">",
"      Yetiser S, Tosun F, Kazkayasi M. Facial nerve paralysis due to chronic otitis media. Otol Neurotol 2002; 23:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/42\">",
"      Dubey SP, Larawin V. Complications of chronic suppurative otitis media and their management. Laryngoscope 2007; 117:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/43\">",
"      Penido Nde O, Borin A, Iha LC, et al. Intracranial complications of otitis media: 15 years of experience in 33 patients. Otolaryngol Head Neck Surg 2005; 132:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/44\">",
"      Browning GG, Gatehouse S, Calder IT. Medical management of active chronic otitis media: a controlled study. J Laryngol Otol 1988; 102:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/45\">",
"      Acuin J. Chronic suppurative otitis media. Clin Evid (Online) 2007; 2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/46\">",
"      Macfadyen CA, Acuin JM, Gamble C. Systemic antibiotics versus topical treatments for chronically discharging ears with underlying eardrum perforations. Cochrane Database Syst Rev 2006; :CD005608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/47\">",
"      Macfadyen CA, Acuin JM, Gamble C. Topical antibiotics without steroids for chronically discharging ears with underlying eardrum perforations. Cochrane Database Syst Rev 2005; :CD004618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/48\">",
"      Klein JO. Strategies for decreasing multidrug antibiotic resistance: role of ototopical agents for treatment of middle ear infections. Am J Manag Care 2002; 8:S345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/49\">",
"      Weber PC, Roland PS, Hannley M, et al. The development of antibiotic resistant organisms with the use of ototopical medications. Otolaryngol Head Neck Surg 2004; 130:S89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/50\">",
"      Roland PS, Stewart MG, Hannley M, et al. Consensus panel on role of potentially ototoxic antibiotics for topical middle ear use: Introduction, methodology, and recommendations. Otolaryngol Head Neck Surg 2004; 130:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/51\">",
"      Matz G, Rybak L, Roland PS, et al. Ototoxicity of ototopical antibiotic drops in humans. Otolaryngol Head Neck Surg 2004; 130:S79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/52\">",
"      Haynes DS, Rutka J, Hawke M, Roland PS. Ototoxicity of ototopical drops--an update. Otolaryngol Clin North Am 2007; 40:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/53\">",
"      Tong MC, Woo JK, van Hasselt CA. A double-blind comparative study of ofloxacin otic drops versus neomycin-polymyxin B-hydrocortisone otic drops in the medical treatment of chronic suppurative otitis media. J Laryngol Otol 1996; 110:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/54\">",
"      Deitmer T. Topical and systemic treatment for chronic suppurative otitis media. Ear Nose Throat J 2002; 81:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/55\">",
"      Pick RM. Lasers in dentistry: soft tissue procedures. CDS Rev 1992; 85:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/56\">",
"      Mir&oacute; N. Controlled multicenter study on chronic suppurative otitis media treated with topical applications of ciprofloxacin 0.2% solution in single-dose containers or combination of polymyxin B, neomycin, and hydrocortisone suspension. Otolaryngol Head Neck Surg 2000; 123:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/57\">",
"      Manolidis S, Friedman R, Hannley M, et al. Comparative efficacy of aminoglycoside versus fluoroquinolone topical antibiotic drops. Otolaryngol Head Neck Surg 2004; 130:S83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/58\">",
"      Agro AS, Garner ET, Wright JW 3rd, et al. Clinical trial of ototopical ofloxacin for treatment of chronic suppurative otitis media. Clin Ther 1998; 20:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/59\">",
"      Suzuki K, Nishimura T, Baba S, et al. Topical ofloxacin for chronic suppurative otitis media and acute exacerbation of chronic otitis media: optimum duration of treatment. Otol Neurotol 2003; 24:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/60\">",
"      Mehta RP, Rosowski JJ, Voss SE, et al. Determinants of hearing loss in perforations of the tympanic membrane. Otol Neurotol 2006; 27:136.",
"     </a>",
"    </li>",
"    <li>",
"     Jackson C. The chronic draining ear. In: Current Therapy in Otolaryngology-Head &amp; Neck Surgery, Gates GA (Ed), Mosby, Baltimore 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/62\">",
"      Takahashi H, Sato H, Nakamura H, et al. Correlation between middle-ear pressure-regulation functions and outcome of type-I tympanoplasty. Auris Nasus Larynx 2007; 34:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/63\">",
"      Mishiro Y, Sakagami M, Kitahara T, et al. The investigation of the recurrence rate of cholesteatoma using Kaplan-Meier survival analysis. Otol Neurotol 2008; 29:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/64\">",
"      Omran A, De Denato G, Piccirillo E, et al. Petrous bone cholesteatoma: management and outcomes. Laryngoscope 2006; 116:619.",
"     </a>",
"    </li>",
"    <li>",
"     Sheehy JL. Tympanoplasty: outer surface grafting technique. In: Otologic Surgery, Brackmann D, Shelton C, Arriaga M (Eds), WB Saunders, Philadelphia 1994. p.121.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/66\">",
"      Stankovic MD. Audiologic results of surgery for cholesteatoma: short- and long-term follow-up of influential factors. Otol Neurotol 2008; 29:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/67\">",
"      Dornhoffer JL, Smith J, Richter G, Boeckmann J. Impact on quality of life after mastoid obliteration. Laryngoscope 2008; 118:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/68\">",
"      Lee YH, Lee NJ, Kim JH, Song JJ. CT, MRI and gallium SPECT in the diagnosis and treatment of petrous apicitis presenting as multiple cranial neuropathies. Br J Radiol 2005; 78:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/69\">",
"      Glasscock ME 3rd, Johnson GD, Poe DS. Surgical management of cholesteatoma in an only hearing ear. Otolaryngol Head Neck Surg 1990; 102:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/70\">",
"      Cvjetkovi�� N, Velepic MS, Velepic MM, et al. The quantitative analysis of the vascularization following two basic auditory canal skin incisions. Coll Antropol 2003; 27:279.",
"     </a>",
"    </li>",
"    <li>",
"     Kemink J, Niparko J. Ossicular disorders in chronic otitis media. In: Current Therapy in Otolaryngology: Head &amp; Neck Surgery, Gates GA (Ed), Mosby, Baltimore 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/72\">",
"      Kim HH, Battista RA, Kumar A, Wiet RJ. Should ossicular reconstruction be staged following tympanomastoidectomy. Laryngoscope 2006; 116:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/26/1450/abstract/73\">",
"      Roth JA, Pandit SR, Soma M, Kertesz TR. Ossicular chain reconstruction with a titanium prosthesis. J Laryngol Otol 2009; 123:1082.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15312 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_26_1450=[""].join("\n");
var outline_f1_26_1450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14110098\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26969753\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26969760\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26969774\">",
"      Chronic otitis media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26969790\">",
"      Cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26969804\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H178692471\">",
"      Chronic otitis media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26969826\">",
"      Cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26969833\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25111276\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98017535\">",
"      Chronic suppurative otitis media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98017516\">",
"      Cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20907628\">",
"      - Primary cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20907635\">",
"      - Secondary cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H178692374\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H178692851\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H178692479\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H178692489\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H178692617\">",
"      Mastoiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H178692644\">",
"      Facial nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H178692651\">",
"      Intracranial complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26969894\">",
"      MEDICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20907773\">",
"      Aural toilet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20908957\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14108070\">",
"      - Topical antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14108077\">",
"      - Systemic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26969910\">",
"      SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26969917\">",
"      Cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26969931\">",
"      Mastoidectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14109348\">",
"      Tympanoplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26969938\">",
"      Ossicular chain reconstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14110098\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/15312\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/15312|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/31/26099\" title=\"figure 1\">",
"      Tympanic membrane anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/15312|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/15/27888\" title=\"picture 1\">",
"      TM perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/8/6272\" title=\"picture 2\">",
"      Cholesteatoma pars flaccida",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/54/21344\" title=\"picture 3\">",
"      Early congenital cholesteatoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/31/14836\" title=\"picture 4\">",
"      Mastoid bowl",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39913?source=related_link\">",
"      Acute otitis media in adults (suppurative and serous)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=related_link\">",
"      Acute otitis media in children: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21514?source=related_link\">",
"      Acute otitis media in children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42808?source=related_link\">",
"      Cholesteatoma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26184?source=related_link\">",
"      Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24728?source=related_link\">",
"      Evaluation of otorrhea (ear discharge) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=related_link\">",
"      External otitis: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_26_1451="Oral appliance adverse effects";
var content_f1_26_1451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Short-term side effects of oral appliances",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Dental discomfort, especially upper and lower incisors",
"       </td>",
"       <td>",
"        33 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Temporomandibular joint pain",
"       </td>",
"       <td>",
"        12.5 to 33 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dry mouth",
"       </td>",
"       <td>",
"        28 to 46 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salivation",
"       </td>",
"       <td>",
"        38 to 50 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gum irritation",
"       </td>",
"       <td>",
"        20 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bruxism",
"       </td>",
"       <td>",
"        12.5 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_26_1451=[""].join("\n");
var outline_f1_26_1451=null;
var title_f1_26_1452="Wells criteria and modified Wells criteria";
var content_f1_26_1452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Wells criteria and modified Wells criteria: clinical assessment for pulmonary embolism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Clinical symptoms of DVT (leg swelling, pain with palpation)",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other diagnosis less likely than pulmonary embolism",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart rate &gt;100",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immobilization (&ge;3 days) or surgery in the previous four weeks",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous DVT/PE",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoptysis",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Probability",
"       </td>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Traditional clinical probability assessment (Wells criteria)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        High",
"       </td>",
"       <td>",
"        &gt;6.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Moderate",
"       </td>",
"       <td>",
"        2.0 to 6.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Low",
"       </td>",
"       <td>",
"        &lt;2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Simplified clinical probability assessment (Modified Wells criteria)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PE likely",
"       </td>",
"       <td>",
"        &gt;4.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PE unlikely",
"       </td>",
"       <td>",
"        &le;4.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from van Belle, A, et al. JAMA 2006; 295:172.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_26_1452=[""].join("\n");
var outline_f1_26_1452=null;
var title_f1_26_1453="DSM-IV-TR diagnostic criteria for schizophrenia";
var content_f1_26_1453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F54426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F54426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR diagnostic criteria for schizophrenia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        A. Characteristic symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two (or more) of the following, each present for a significant portion of time during a 1-month period (or less if successfully treated)*:",
"        <ol>",
"         <li>",
"          Delusions",
"         </li>",
"         <li>",
"          Hallucinations",
"         </li>",
"         <li>",
"          Disorganized speech (eg, frequent derailment or incoherence)",
"         </li>",
"         <li>",
"          Grossly disorganized or catatonic behavior",
"         </li>",
"         <li>",
"          Negative symptoms, ie, affective flattening, alogia, or avolition",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        B. Social/occupational dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For a significant portion of the time since the onset of the disturbance, one or more major areas of functioning such as work, interpersonal relations, or self-care are markedly below the level achieved prior to the onset (or when the onset is in childhood or adolescence, failure to achieve expected level of interpersonal, academic, or occupational achievement).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        C. Duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Continuous signs of the disturbance persist for at least 6 months. This 6-month period must include at least 1 month of symptoms (or less if successfully treated) that meet Criterion A (ie, active-phase symptoms) and may include periods of prodromal or residual symptoms. During these prodromal or residual periods, the signs of the disturbance may be manifested by only negative symptoms or two or more symptoms listed in Criterion A present in an attenuated form (eg, odd beliefs, unusual perceptual experiences).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        D. Schizoaffective and mood disorder exclusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schizoaffective disorder and mood disorder with psychotic features have been ruled out because either (1) no major depressive, manic, or mixed episodes have occurred concurrently with the active-phase symptoms; or (2) if mood episodes have occurred during active-phase symptoms, their total duration has been brief relative to the duration of the active and residual periods.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        E. Substance/general medical condition exclusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The disturbance is not due to the direct physiological effects of a substance (eg, a drug of abuse, a medication) or a general medical condition.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        F. Relationship to a pervasive developmental disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If there is a history of autistic disorder or another pervasive developmental disorder, the additional diagnosis of schizophrenia is made only if prominent delusions or hallucinations are also present for at least a month (or less if successfully treated).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Note:",
"    </strong>",
"    Classification of longitudinal course (can be applied only after at least 1 year has elapsed since the initial onset of active-phase symptoms):",
"    <br>",
"     <ul>",
"      <li>",
"       Episodic with interepisode residual symptoms (also specify if: with prominent negative symptoms)",
"      </li>",
"      <li>",
"       Episodic with no interepisode residual symptoms",
"      </li>",
"      <li>",
"       Continuous (also specify if: with prominent negative symptoms)",
"      </li>",
"      <li>",
"       Single episode in partial remission (also specify if: with prominent negative symptoms)",
"      </li>",
"      <li>",
"       Single episode in full remission",
"      </li>",
"      <li>",
"       Other or unspecified pattern",
"      </li>",
"     </ul>",
"     <div class=\"footnotes\">",
"      * Only one Criterion A symptom is required if delusions are bizarre or hallucinations consist of a voice keeping up a running commentary on the person's behavior or thoughts, or two or more voices conversing with each other.",
"     </div>",
"     <div class=\"reference\">",
"      Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (Copyright &copy; 2000). American Psychiatric Association.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_26_1453=[""].join("\n");
var outline_f1_26_1453=null;
var title_f1_26_1454="Polyp colonoscopy PI";
var content_f1_26_1454=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F72330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F72330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colonic polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 194px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Virtual colonoscopy shows a small polyp (arrow) in the transverse colon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_26_1454=[""].join("\n");
var outline_f1_26_1454=null;
var title_f1_26_1455="Proximal phalanx condylar fracture AP xray";
var content_f1_26_1455=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Condylar fracture of the proximal phalanx: AP view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 544px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This AP x-ray shows a condylar fracture at the head of the proximal phalanx. These fractures most often involve one condyle and are unstable.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_26_1455=[""].join("\n");
var outline_f1_26_1455=null;
